TM’s 3rd World Molecular & Cell Biology Online Conference by Romano, MARIA FIAMMETTA
1 
 
 
 
 
 
Conference Handbook 
 
 
 
TM’s 3rd World Molecular & Cell Biology 
Online Conference 
 
 
 February 25-28, 2014 
 
                                         
 
 
 
  
                                       
     
 
 
 
 
 
 
2 
 
Dear colleagues 
Thank you so much for taking time out of your busy schedule to participate in online 
conference - TM’s 3rd World Molecular & Cell Biology Online Conference, which 
will be held on February 25-28, 2014. It will be very helpful to speakers, attendees, and 
other related people. Target Meeting appreciates your attendances and generous 
contribution. We hope you will enjoy the difference.  
Sincerely Yours 
Target Meeting Team in USA 
 
Preparation in advance: USB headset with microphone  
 
 
                                                      Instructions 
 
1. You can receive all 4 conference track links before the event. You can participate in 
all or part of tracks (sessions). It depends on your time or interest.  
 
2. Double click the track links at scheduled date & time to join the conference. The 
conference component software will be downloaded and installed on your computer 
automatically (about 30 seconds) when you click the track links. If not, please manually 
download the component software on your computer after you click the track links. 
Normally the component software will be saved in the download folder, my document, 
desktop, or somewhere. It depends on your computer. Double click it to run this software 
(You must have right to install software on your computer). Then you will enter the 
“Conference Room”. It is completely secure.  
 
3. Connect USB headset to your computer. If your audio devices are connected correctly, 
you will see the sound meters in the Control Panel light up green. Your USB headset is 
muted during the conference in case of background noise. If you want to talk with other 
speakers at the Q&A sessions, please click the icon “hand” on the conference control 
panel. The conference organizer will unmute your headset, then you can discuss with 
them in real time. The session chair will be unmuted at the beginning and end of each 
presentation. So the chair can introduce the speakers and organize the Q&A sessions. At 
the panel discussion sessions, all speakers are unmute.  
 
4. When you give oral presentation, please open your PowerPoint file (presentation 
slides) in full screen on your computer. Conference organizer will pass the Presenter 
Control Panel to you. Your USB headset will be unmuted automatically. Click Show My 
Screen on the Presenter Control Panel. You can start your presentation after the chair’s 
introduction. Never close the control panel on your computer during the sessions. Please 
type messages in the control panel and sent it to organizers if you have any questions 
during the conference. Organizers will reply you in private. 
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                                                  Conference Partners 
 
For more than four decades, LI-COR(R) Biosciences has 
been helping scientists advance discovery by providing 
innovative research tools. And with more than twenty 
years of experience in biotechnology, LI-COR is now a 
leading manufacturer of near-infrared imaging platforms, 
analysis software, and IRDye(R) infrared dye reagents. LI-COR pioneered the 
development of near-infrared fluorescence systems for DNA sequencing, and today 
provides systems for drug discovery, protein research, small animal imaging, and 
undergraduate training. These tools provide research solutions for a wide variety of 
applications, including quantitative Western blotting, small animal imaging, and cell-
based assays. Research toward a Cure is part of our ongoing effort to develop research 
tools and highlight techniques that enhance scientists' technical capabilities to advance 
cancer research. Currently, thousands of LI-COR systems are being used in laboratories 
around the world for advanced research and drug development. Our website features 
published examples of applications and techniques where infrared fluorescence detection 
contributes to the understanding of cancer and the search for cures. Please visit 
www.licor.com/cancer for more information. In addition to the biotechnology lines of 
instruments and reagents, LI-COR instruments for photosynthesis, carbon dioxide 
analysis, and light measurement are recognized worldwide for standard-setting 
innovation in plant science research and environmental monitoring. Founded in 1971, the 
privately held company is based in Lincoln, Nebraska, with subsidiaries in Germany and 
the United Kingdom. LI-COR systems are used in over 100 countries and are supported 
by a global network of distributors.  
 
Leica Microsystems is a world leader in microscopes and 
scientific instruments. Founded as a family business in 
the nineteenth century, the company’s history was 
marked by unparalleled innovation on its way to 
becoming a global enterprise. Leica Microsystems’ Life 
Science Division supports the imaging needs of the 
scientific community with advanced innovation and technical expertise for the 
visualization, measurement and analysis of microstructures. Our strong focus on 
understanding scientific applications puts Leica Microsystems’ customers at the leading 
edge of science. Its historically close cooperation with the scientific community is the key 
to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates 
solutions tailored to their requirements. At the global level, Leica Microsystems is 
organized in three divisions, all of which are among the leaders in their respective fields: 
the Life Science Division, Industry Division, and Medical Division. Leica Microsystems 
has six manufacturing facilities in five countries, with sales and service organizations in 
20 countries. The company is headquartered in Wetzlar, Germany. For current Leica 
promotions: http://www.leica-microsystems.com/ls-promos.  
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If you are seeking reliable, top performing, budget 
friendly laboratory instruments, you’ve come to the right 
place. Our Bullet Blender tissue homogenizers, 
automated blot processors, rockers, and CO2 induction 
systems are engineered to automate mundane tasks and 
reduce errors. 4 Reasons to Rely on Next Advance 
Laboratory Instruments: 1. You’ll save time and recognize more accurate and consistent 
results 2. Our innovative technology and elegant design = superior results at lower costs 
3. Product design is driven by the laboratory and budget requirements of biologists 4. 
Made in the U.S.A., all of our products are reliable, robust and built to last. Please visit 
http://www.nextadvance.com for more information. 
 
Principal Investigators Association (PIA) is an independent 
organization created to communicate and promote among 
scientists in all fields of research best practices and 
continuing professional development. The information and 
advice we provide covers such topics as garnering financial 
support and optimally using monetary, material and personnel resources to increase the 
scope, efficiency and productivity of your scientific inquiry. PIA offers a variety of 
product formats designed to fit your busy lives. These include live and on-demand 
Webinars, grant-writing manuals, funding and lab management executive reports, 
educational packs and toolkits, free white papers and a free bi-monthly eNewsletter. 
 
Medical News Today is the largest independent medical 
and health news site on the web - with over 2,500,000 
unique monthly users it is ranked number one for medical 
news on Google and Yahoo!. Medical News Today is used 
by Blue Chip pharmaceutical and health organizations,   
advertising agencies, PR companies and vertical ad networks to deliver targeted 
disease/condition and general health campaigns. For more information, please visit 
www.medicalnewstoday.com. 
 
F1000Prime is an online tool to help life scientists and 
clinicians keep on top of current literature. Our peer-
nominated global 'Faculty' of over 5000 leading scientists 
and clinicians identify and write recommendations for the 
best published research articles across biology and 
medicine, creating the world's first and largest searchable database of recommendations 
for over 150,000 life science-related articles. Our Faculty Members and article 
recommendations are organized into 40 faculties, which are further subdivided into 300 
sections. In this way, published literature from every field of biology and medicine is 
comprehensively and systematically reviewed by an expert panel of scientists and 
clinicians. At F1000Prime, we pride ourselves on bringing focus to all great research 
articles, regardless of journal impact factor. 
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PharmaVOICE magazine, reaching more than 34,000 BPA-
qualified life-sciences executives, is the forum that allows 
business leaders to engage in a candid dialogue on the 
challenges and trends impacting the industry. 
PharmaVOICE provides readers with insightful and 
thought-provoking commentary in a multiple-perspective format through forums, topics, 
and articles covering a range of issues from molecule through market. PharmaVOICE 
subscribers are also kept abreast of the latest trends and information through additional 
media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, 
White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com 
provides a comprehensive directory of products, services, and solutions for the life-
sciences industry. 
 
Cancer Cell International is an online, open access journal 
published by BioMed Central.  We publish articles on all 
aspects of cancer cell biology, originating largely from 
work using cell culture techniques. Much of cancer work 
relates to biological experiments in which cells are grown 
in vitro, in two- or three-dimensional systems. Such experiments have provided crucial 
data in many fields, from the chemoattraction of immune cells or blood vessel endothelial 
cells (angiogenesis), to measurements of effective doses of drugs, irradiation and other 
modalities. Cancer Cell International considers manuscripts that include animal work (in 
vivo) only if the work is a logical progression from previous work in vitro. Please visit 
the website  www.cancerci.com  for more information or for editorial enquiries please 
contact editorial@cancerci.com. 
 
20/20 Pharma, published by IMI, is a magazine and website 
which presents insightful analysis of current events, 
developments, and trends in the pharmaceutical world.The 
publication has forged powerful relationships with key 
industry leaders to provide a platform for decision makers 
to have the means to procure and plan implementation strategies based on the topics 
covered.   
 
The heat is on for an online social networking community 
for nanoscientists. The International Nanoscience 
Community, TINC, was cooked up by Hungarian chemistry 
PhD student Andras Paszternak. It now provides a rich 
menu of communication tools for the international 
community of scientists working in the growing field of nanoscience and nanotechnology 
and recently passed the 4900 members mark. The virtual nano community is fully 
equipped with all the functions one expects from a modern online networking site: 
personal chat, a scientific forum, more than 95 thematic groups, including microscopy, 
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nanomedicine, and even a discussion forum on safety and toxicity. 
http://www.nanopaprika.eu.  
 
World Conference Calendar is a directory publishing 
information on academic conferences all over the world. 
Knowledge is really appreciated only when it reached a 
user. Conferences are one of the best environments that this 
knowledge is delivered to a large audience. As World 
Conference Calendar, we are trying to be an effective medium to point out where these 
exchanges will take place. 
 
Clocate.com is a leading international search engine and 
directory for worldwide conferences and exhibitions. The 
events cover the following areas: Industry and 
manufacturing, Health and medicine, Technology and IT, 
Business and finance, sciences, education, services 
(banking, insurance, tourism, Hospitality and more), government, environment, life style 
and arts. The details for each event include: description, dates, location, address, prices 
and more. 
 
BioSpectrum Asia is the most influential source of 
information for life sciences industry and is uniquely 
positioned as a specialized B2B information platform in 
Asia Pacific region. The magazine provides comprehensive 
coverage and useful insights in the areas of 
pharmaceuticals, biotechnology, medical devices, research & development and policies. 
 
Business with India (www.businesswithindia.in) is a 
leading portal providing help and assistance to find new 
business partners and track global business opportunity. 
Any Product, Any Service, Anywhere in the World.  
 
 
Biology51 (www.51atgc.com) is a very instructive 
biological video website. Based on abundant experiences 
and advantages on biotechnology, the people of this web 
constructed an expert photographic center in a myria-
laminar flow experiment-shooting lab. The expert 
biotechnological team and photographic team took a lot of operational videos on cell 
biology, molecular cloning, proteomics, animal models and virology etc. The very huge 
experimental video libraries could give the unlimited benefits to research people on high-
stage experimental technologies, including easily direct observation to all kinds of 
experiments etc. So she has unique priority to do advertising for biological companies.   
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                                          Conference Program  
                                  (All Times Are New York Time) 
 
Track 1: 8:30AM – 17:30 PM, February 25, 2014 
 
                Session 1: Cell signaling pathways-I 
                                  9:00 AM – 11:00 AM 
 
                Session 2: Cell signaling pathways-II 
                                  11:00 AM – 13:30 PM 
 
                Session 3: Cell signaling pathways-III 
                                   13:30 PM – 15:30 PM 
      
                Session 4: Cell signaling pathways-IV 
                                 15:30 PM – 17:30 PM 
 
Track 2: 8:30 AM – 17:30 PM, February 26, 2014 
 
                Session 5: Molecular Mechanisms of Cancer-I 
                                 9:00 AM – 11:00 AM 
 
                Session 6: RNA biology-I 
                                 11:00 AM – 13:00 PM 
 
                Session 7: RNA biology-II 
                                 13:00 PM – 15:00 PM 
 
                Session 8: Molecular mechanisms of cancer-II 
                                 15:00 PM – 17:30 PM 
 
Track 3: 8:30 AM – 16:30 PM, February 27, 2014 
 
                Session 9: GPCR structure and function 
                                 9:00 AM – 10:30 AM 
 
                Session 10: Cell Death 
                                 10:30 AM – 12:00 PM 
 
                Session 11: Stem cell biology-I 
                                 12:00 PM – 14:30 PM 
 
                Session 12: Cell signaling pathways-V 
                                 14:30 PM – 16:30 PM 
 
Track 4:  8:30 AM – 17:00 PM, February 28, 2014 
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                Session 13: General biochemistry-I 
                                 9:00 AM – 11:00 AM 
 
                Session 14: General biochemistry-II 
                                 11:00 AM – 13:00 PM 
 
                Session 15: Stem cell biology-II 
                                 13:00 PM – 15:00 PM 
 
                Session 16: General biochemistry-III 
                                 15:00 PM – 17:00 PM 
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Track 1: 8:30 AM– 17:30 PM, February 25, 2014 
 
8:30 – 9:00 AM  
Speakers and attendees can login the online conference. 
 
Session 1: Cell signaling pathways-I 
9:00 AM – 11:00 AM 
Session Chair: Dr. Vincenza Rita Lo Vasco 
 
9:00 – 9:30 AM 
Presentation Title: Slow Regulated Release of H2S Inhibits Oxidative Stress Induced 
Cell Death by Influencing Certain Key Signaling Molecules. 
Aman Shah Abdul Majid, PGDPharm, MD, PhD, Medical Lecturer, Department of 
Integrative Medicine, Advanced Medical and Dental Institute, USM, Penang, Malaysia. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
9:30 – 10:00 AM 
Presentation Title: From molecules to genes.  
Amol Patil, Associate Professor, Dept. of Orthodontics and Dentofacial Orthopedics, 
Bharati Vidyapeeth Dental College and Hospital, Bharati Vidyapeeth Deemed 
University, India. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:00 – 10:30 AM 
Presentation Title: Signal transduction in innate immunity - what can we learn from the 
Caspase Activation Domains (CARDs) of the NLR family members NOD1 and NOD2. 
Tom Monie, Researcher, Department of Biochemistry, University of Cambridge, 
Cambridge, UK. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:30 – 11:00 PM 
Presentation Title: The involvement of Phosphoinositide signal transduction pathway in 
angiogenesis.  
Vincenza Rita Lo Vasco, MD, PhD, Assistant Professor, Department of Sensitive 
Organs, Sapienza University of Rome, Rome, Italy.   
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 2: Cell signaling pathways-II 
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11:00 AM – 13:30 PM 
Session Chair: Dr. Dan Cojoc 
 
11:00 – 11:30 PM 
Presentation Title: Is it possible to fight influenza by targeting intracellular redox state? 
Rossella Sgarbanti, Assistant Professor, Università Telematica San Raffaele, IRCCS 
San Raffaele Roma, Italy. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
11:30 – 12:00 PM 
Presentation Title: Focal stimulation of neuronal cells by optical manipulation.  
Dan Cojoc, Senior Scientist, IOM-CNR, Institute of Materials- National Research 
Council, Italy. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
12:00 – 12:30 PM 
Presentation Title: Pax3 and Pax7 reversely interact and regulate the expression and 
distribution of their target genes in the chicken developing spinal cord.  
Juntang Lin, Professor, Department of Life Science and Technology, Xinxiang Medical 
University, Henan Province, P. R. China; Group leader, Institute of Anatomy I, Klinikum 
der Friedrich-Schiller-Universität, Germany. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
12:30 – 13:00 PM 
Presentation Title: Heme oxygenase ameliorates cardiomyopathy by suppressing 
markers of heart failure and inflammation in normoglycemic obese rats".  
Joseph Fomusi Ndisang, Associate Professor, Department of Physiology, University of 
Saskatchewan, Canada. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
13:00 – 13:30 PM 
Presentation Title: Rethinking the Traditional Western.  
John Lyssand, Ph.D., Field Applications Scientist, Biotechnology, LI-COR Biosciences, 
USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 3: Cell signaling pathways-III 
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13:30 PM – 15:30 PM 
Session Chair: Dr. Jamil Talukder 
 
13:30 – 14:00 PM 
Presentation Title: Signaling Mechanisms Underlying Alcohol Abuse Disorders. 
Dorit Ron Ph.D., Professor, Endowed Chair in Cell Biology of Addiction in Neurology, 
Department of Neurology, University of California, San Francisco, Gallo Research 
Center Investigator, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
14:00 – 14:30 PM 
Presentation Title: Leukotriene activates Ca2+ dependent dephosphorylation of ASCT1 
to down regulate Ala transport in IEC-6 cells.  
Jamil Talukder, DVM, PhD, Associate Professor, Biology, LeMoyne-Owen College, 
USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
14:30 – 15:00 PM 
Presentation Title: Regulation of osteoclast differentiation by Cx37.   
Lilian I. Plotkin, PhD, Assistant Professor, Department of Anatomy and Cell Biology, 
Indiana University School of Medicine, USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
15:00 – 15:30 PM 
Presentation Title: Pending  
Tammy A. Butterick-Peterson, Ph.D., Adjunct Assistant Professor, Minnesota Obesity 
Neuroscience Lab Group, University of Minnesota, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 4: Cell signaling pathways-IV 
15:30 PM – 17:30 PM 
Session Chair: Dr. Zhen He 
 
15:30 – 16:00 PM 
Presentation Title: Development of sexually dimorphic nuclei and the influence of 
estrogen-like compound exposure.  
Zhen He, MD, PhD, Staff Fellow/Neuroanatomist, Division of Neurotoxicology, HFT-
132, National Center for Toxicological Research, Food and Drug Administration, USA.  
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Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:00 – 16:30 PM 
Presentation Title: Proline Glutamic acid and Leucine rich Protein1 (PELP1) is a novel 
coregulator of β-catenin in glioblastoma.  
Gangadhara Reddy Sareddy, Researcher, The University of Texas Health Science 
Center at San Antonio, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:30 – 17:00 PM 
Presentation Title: Friend or foe: Anti-aging cosmetics on the eye.   
Juan Ding, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard 
Medical School, Boston, MA, USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
17:00 – 17:30 PM 
Presentation Title: The inflammatory factors and their epigenetic regulation in Multiple 
sclerosis.  
Fanglin Zhang, Scientist, Department of Neurology, Multiple Sclerosis Research Center, 
Vanderbilt University Medical Center, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Track 2: 8:30 AM – 17:30 PM, February 26, 2014 
 
8:30 – 9:00 AM  
Speakers and attendees can login the online conference. 
 
Session 5: Molecular Mechanisms of Cancer-I 
9:00 AM – 11:00 AM 
Session Chair: Dr. Romano Maria Fiammetta 
 
9:00 – 9:30 AM 
Presentation Title: Prostate cancer stem cell, midkine protein and lithium chloride. 
Mine Erguven, Istanbul Aydın University, Faculty of Health Sciences, Istanbul, Turkey. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
9:30 – 10:00 AM 
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Presentation Title: NO-releasing doxorubicins: new anthracycline derivatives that 
overcomes drug-resistance in cancer cells.  
Chiara Riganti, MD, Assistant Professor of Biochemistry, Department of Oncology, 
Turin School of Medicine, University of Turin, Italy.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:00 – 10:30 AM 
Presentation Title: FKBP51 orchestrates the evil axis EMT/ cancer stemness/drug 
resistance, in malignant melanoma: a matter of protein/protein interaction.  
Romano Maria Fiammetta, Professor & Group leader, Department of Biochemistry and 
Medical Biotechnology, Federico II University of Naples, Naples, Italy. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:30 – 11:00 PM 
Presentation Title: Diagnostic yield of primary circulating tumor cells in women with 
suspicion of breast cancer: Study BEST (Breast Early Screening Test).  
Nigel P Murray, Subdivisión de Hematologóa, Hospital de Carabineros, Nuñoa, 
Santiago, Chile.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 6: RNA biology-I 
11:00 AM – 13:00 PM 
Session Chair: Dr. Erik Wiemer 
 
11:00 – 11:30 AM 
Presentation Title: MicroRNAs in the tumor biology of soft tissue sarcomas.  
Erik Wiemer Ph.D., Associate Professor, Dept. of Medical Oncology, Erasmus 
University Medical Center, Netherland. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
11:30 – 12:00 PM 
Presentation Title: Regulation of Tissue Factor biology via microRNAs.  
Andreas Eisenreich, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, 
Centrum für Herz- und Kreislaufmedizin, 12200 Berlin, Germany. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
12:00 – 12:30 PM 
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Presentation Title: Functions of p63 and its miR-205 target in cell migration and 
metastasis.   
Paola Tucci, Ph.D., Assistant Professor, Department of Pharmacy, Health 
and Nutritional Sciences, University of Calabria, Italy.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
12:30 – 13:00 PM 
Presentation Title: Sexually dimorphic microRNA expression: a new thought on sex 
bias of autoimmune diseases.  
Rujuan Dai, Assistant Professor, Department of Biomedical Sciences and Pathology, 
Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, 
VA24060, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 7: RNA biology-II 
13:00 PM – 15:00 PM 
Session Chair: Dr. Kathleen L. Hefferon 
 
13:00 – 13:30 PM 
Presentation Title: Applications of Virus Expression Vectors for Infectious Disease 
Research. 
Kathleen L. Hefferon, Professor, University of Toronto, Canada. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
13:30 – 14:00 PM 
Presentation Title: MicroRNAs in the malignant transformation of colon adenoma to 
Adenocarcinoma.  
Subbaya Subramanian, Assistant Professor, Department of Surgery, The University of 
Minnesota, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
14:00 – 14:30 PM 
Presentation Title: lncRNA 7SL represses p53 translation by competing with HuR. 
Kotb Abdelmohsen, Senior Scientist, Laboratory of Cellular and Molecular Biology, 
NIA-IRP, NIH, Baltimore, MD, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
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14:30 – 15:00 PM 
Presentation Title: Reciprocal regulation of microRNA and long non-coding RNAs in 
cancer cells. 
Yin-Yuan Mo, Professor, Cancer Institute, University of Mississippi Medical Center, 
Jackson, MS, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 8: Molecular mechanisms of cancer-II 
15:00 PM – 17:30 PM 
Session Chair: Dr. Christina Voelkel-Johnson 
 
15:00 – 15:30 PM 
Presentation Title: Tumor-stromal crosstalk in pancreatic cancer pathobiology and 
chemoresistance.  
Ajay Singh, Associate Professor, Department of Oncologic Sciences, Mitchell Cancer 
Institute, University of South Alabama, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
15:30 – 16:00 PM 
Presentation Title: Sphingosine kinase 2 as a novel therapeutic target in prostate cancer. 
Christina Voelkel-Johnson. PhD., Associate Professor of Microbiology and 
Immunology, Department of Microbiology & Immunology, Medical University of South 
Carolina, Charleston SC, USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:00 – 16:30 PM 
Presentation Title: Cell Directionality as an Indicator of Breast Cancer Progression. 
Christina Stuelten, Scientist, Cell and Cancer Biology Branch, National Cancer 
Institute, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:30 – 17:00 PM 
Presentation Title: Deficient Aldehyde Dehydrogenase 1A1 Expression In Primary 
Cells Isolated From Gorlin Syndrome Patients:  Implications For Radiation 
Carcinogenesis and Developmental Defects.    
Thomas Weber, Senior Research Scientist, FSD/Cell Biology and Biochemistry, Pacific 
Northwest National Laboratory, USA. 
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Q&A Session, presenter answers questions from other speakers or attendees. 
 
17:00 – 17:30 PM 
Presentation Title: Vesicular trafficking protein, Rab25 is a conditional oncogene in 
breast cancer.  
Shreya Mitra, Researcher, Department of Systems Biology, University of Texas MD 
Anderson Cancer Center, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Track 3: 8:30 AM– 16:30 PM, February 27, 2014 
 
8:30 – 9:00 AM  
Speakers and attendees can login the online conference. 
 
Session 9: GPCR structure and function 
9:00 AM – 10:30 AM 
Session Chair: Dr. Anwar Rayan 
 
9:00 – 9:30 AM 
Presentation Title: Profiling the Pharmacology of GPCR Complexes  
Kevin Pfleger, Associate Professor, Molecular Endocrinology-GPCRs, Western 
Australian Institute for Medical Research, Australia.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
9:30 – 10:00 AM 
Presentation Title: Indexing Chemicals for their Bioactivity on GPCRs by Ligand-
Structural Combined Approach.   
Anwar Rayan, Head of the Drug Discovery Informatics Lab at the QRC research center 
– Al Qasemi Academic College & CEO of GeneArrest LTD company, Israel. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:00 – 10:30 AM 
Presentation Title: Expressioneering Technology accelerates Functional Expression and 
Crystallization of GPCRs for Drug Discovery.  
Saurabh Sen, Senior Scientist, R&D, Lucigen Corp, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
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discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 10: Cell death 
10:30 AM – 12:00 PM 
Session Chair: Dr. Giulia Grisendi 
 
10:30 – 11:00 PM 
Presentation Title: Monte Carlo simulation elucidates the type 1/ type 2 choice in 
apoptosis under death ligand induction.  
Subhadip Raychaudhuri, Associate Professor, Indraprastha Institute of Information 
Technology, India. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
11:00 – 11:30 PM 
Presentation Title: Gene modified mesenchymal progenitor cells for cancer gene 
therapy.  
Giulia Grisendi, PhD, Researcher, Department of Medical and Surgical Sciences for 
Children & Adults, University Hospital of Modena and Reggio Emilia, Italy.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
11:30 – 12:00 PM 
Presentation Title: Sharpin plays an important role in the regulation of keratinocyte 
apoptosis and skin inflammation.  
Fumiyo Ikeda, PhD, Group leader, Institute of Molecular Biotechnology (IMBA) Dr. 
Bohr-Gasse 3, 1030, Vienna, Austria. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 11: Stem cell biology-I 
12:00 PM – 14:30 PM 
Session Chair: Dr. Ming Pei 
 
12:00 – 12:30 PM 
Presentation Title: Application of human cardiomyocytes derived from pluripotent stem 
cells for toxicity testing and disease modeling.  
Peter Sartipy, PhD, Vice President Stem Cell Discovery and Senior Principal Scientist, 
Cellectis AB, Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
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12:30 – 13:00 PM 
Presentation Title: Limbal Side Population cells for the treatment of limbal stem cell 
deficiency.   
Bakiah Shaharuddin, M.D, M.MED (Ophth), Institute of Genetic Medicine, Newcastle 
University, International Centre for Life, Central Parkway, Newcastle Upon Tyne, NE1 
3BZ, U.K. 
 
Q&A Session, presenter answers questions from other speakers or attendees.  
 
13:00 – 13:30 PM  
Presentation Title: Decellularized stem cell matrix mediated cartilage regeneration and 
its significance for regenerative medicine  
Ming Pei, M.D., Ph.D., Tenured Associate Professor, Director, Stem Cell and Tissue 
Engineering Laboratory, Department of Orthopaedics, West Virginia University, USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
13:30 – 14:00 PM 
Presentation Title: Molecular Elucidation and Engineering of the Stem Cell Fate 
Decisions.  
David Schaffer, Ph.D., Professor of Chemical and Biomolecular Engineering, 
Bioengineering, and the Helen Wills Neuroscience Institute, Director, Berkeley Stem 
Cell Center, University of California, Berkeley, CA, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
14:00 – 14:30 PM 
Presentation Title: Targeting and Tackling the Cancer Stem Cell Niche.   
Lynne-Marie Postovit, PhD, the Sawin-Baldwin Chair in Ovarian Cancer and the Dr. 
Anthony Noujaim Legacy Oncology Chair as well as an associate professor in the 
Department of Oncology at the University of Alberta and an adjunct professor in the 
Department of Anatomy and Cell Biology at Western University, USA.   
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 12: Cell signaling pathways-V 
14:30 PM – 16:30 PM 
Session Chair: Dr. Jianjun Sun 
 
14:30 – 15:00 PM 
Presentation Title: Molecular adaptations of mammalian hibernation; regulation 
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of energy dependent cellular processes during metabolic depression.  
Kenneth B. Storey, Ph.D., F.R.S.C., Professor of Biochemistry at Carleton University in 
Ottawa and holds the Canada Research Chair in Molecular Physiology, Canada. Michael 
Wu, the lab of Dr. Kenneth B. Storey, Carleton University, Canada. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
15:00 – 15:30 PM 
Presentation Title: Anti-inflammatory effects of natural extracts enriched with 
bioactives.  
Alexander Gosslau, Visiting Professor, Department of Chemistry and Chemical 
Biology, Rutgers University, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
15:30 – 16:00 PM 
Presentation Title: Pending. 
Jianjun Sun, Assistant Professor of Biological Sciences, University of Texas at El Paso, 
USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:00 – 16:30 PM 
Presentation Title: Pending.  
Rahul Saxons, Researcher, Department of Biochemistry and Molecular & Cellular 
Biology Georgetown University Medical Center, Washington, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Track 4: 8:30 AM– 17:00 PM, February 28, 2014 
 
8:30 – 9:00 AM  
Speakers and attendees can login the online conference. 
 
Session 13: General biochemistry-I 
9:00 AM – 11:00 AM 
Session Chair: Dr. Tiana V. Curry-McCoy 
 
9:00 – 9:30 AM 
Presentation Title: Surrogate reporter-based enrichment of cells containing RNA-guided 
Cas9 nuclease-induced mutations. 
Suresh Ramakrishna, Stem Cell Research, College of Medicine, Hanyang University, 
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Seoul-133-791, South Korea. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
9:30 – 10:00 AM 
Presentation Title: Genetic polymorphism of milk proteins and their relationship with 
milk compositional traits in Indian goat breeds.  
Ajoy Mandal, Senior Scientist, Eastern Regional Station, National Dairy Research 
Institute, India. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:00 – 10:30 AM 
Presentation Title: Circulating complementary innate IgM originating from ancestral 
antigen completeness in reduction of O-glycosylations.    
Peter Arend, MD, ret. Philipps University of Marburg/Lahn, Germany. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
10:30 – 11:00 PM 
Presentation Title: Alcohol: A Glimpse at Direct, and Indirect Organ Damage; With 
Application to Future Research.  
Tiana V. Curry-McCoy Ph.D., Assistant Professor, Medical Laboratory Imaging 
Radiologic Sciences-Clinical Laboratory Science, College of Allied Health Sciences, 
Georgia Regents University (MCG&ASU), USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 14: General biochemistry-II 
11:00 AM – 13:00 PM 
Session Chair: Dr. Iulia M. Lazar 
 
11:00 – 11:30 PM 
Presentation Title: Novel uses of circular variance for macromolecular analyses.  
Mihaly Mezei, Director of Molecular Modeling Core (associate professor), Department 
of Structural and Chemical Biology, Mount Sinai School of Medicine, NYU, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
11:30 – 12:00 PM 
Presentation Title: The Role of Proteomics in the Elucidation of Cancer Pathways. 
Iulia M. Lazar, Ph.D., Associate Professor, Department of Biological Sciences, Virginia 
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Polytechnic Institute and State University, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
12:00 – 12:30 PM 
Presentation Title: ß-phenylethylamine as a novel inhibitor of E. coli biofilm.  
Birgit M. Pruess, Associate Professor, Veterinary and Microbiological Sciences, North 
Dakota State University, USA.   
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
12:30 – 13:00 PM 
Presentation Title: Modeling the Evolution of Drug Resistance in Malaria.  
David Hecht, Professor of chemistry at Southwestern College in Chula Vista, California 
and an adjunct faculty member, San Diego State University Dept. of Chemistry, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 15: Stem cell biology-II 
13:00 PM – 15:00 PM 
Session Chair: Dr. Devyn M. Smith 
 
13:00 – 13:30 PM 
Presentation Title: Leveraging stem cell discoveries to enable drug discovery?  
Devyn M. Smith, Chief Operating Officer, Pfizer's Neusentis Research Unit, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
13:30 – 14:00 PM 
Presentation Title: Neural Stem Cell Models & Potential Anesthetic-Induced 
Neurotoxicity.  
Cheng Wang, M.D., Ph.D. Senior Scientist at the National Center for Toxicological 
Research (NCTR)/US Food and Drug Administration (FDA), USA. He is also an Adjunct 
Faculty member in the Department of Pharmacology and Toxicology, University of 
Arkansas for Medical Sciences (UAMS), USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
14:00 – 14:30 PM 
Presentation Title: Cardiomyocyte Differentiation in Human Skeletal Muscle Stem 
Cells by Biophysical Factors and Post-Transcriptional Regulation.  
Jason Tchao, MS, Department of Bioengineering, University of Pittsburgh, USA; 
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Kimimasa Tobita, M.D. Research Associate Professor, Director of Animal Imaging 
Core, Rangos Research Center, Children's Hospital of Pittsburgh of UPMC, USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
14:30 – 15:00 PM 
Presentation Title: Age-related dysfunction in mechano-transduction impairs 
differentiation of human mammary epithelial progenitors.  
Fanny Pelissier, Researcher, Life Science Division, Lawrence Berkeley National 
Laboratory, Berkeley, California, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
 
Session 16: General biochemistry-III 
15:00 PM – 17:00 PM 
Session Chair: Dr. Jong Hyun Ham 
 
15:00 – 15:30 PM 
Presentation Title: The intercellular signaling systems for the virulence of the rice 
pathogenic bacterium Burkholderia glumae.   
Jong Hyun Ham, Ph. D., Associate Professor, Department of Plant Pathology and Crop 
Physiology, Louisiana State University Agricultural Center, USA.  
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
15:30 – 16:00 PM 
Presentation Title: Metabolomics, Metaboloepigenomics, Polyomics.  
Miroslava Cuperlovic-Culf, Senior Research Officer, National Research Council of 
Canada, Moncton, Canada. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:00 – 16:30 PM 
Presentation Title: Methamphetamine increases the levels of dopamine D2 receptor and 
dopamine transporter in dopaminergic nerve terminals.  
Anna Moszczynska, Ph.D., Assistant Professor, Department of Pharmaceutical Sciences, 
Rm 3142, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State 
University, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
16:30 – 17:00 PM 
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Presentation Title: Bioprinted Neocartilage Formation in Poly (ethylene) Glycol and 
Gelatin Methacrylate Copolymer Using Human Mesenchymal Stem Cells.  
Xiaofeng Cui, Ph.D., Senior Research Fellow, Institute of Advanced Study, Technical 
University of Munich; Director of Research, Stemorgan Therapeutics, New York, USA. 
 
Q&A Session, presenter answers questions from other speakers or attendees. 
 
Panel Discussion. This session is to provide speakers and attendees with in-depth 
discussion and networking. You can discuss what you want with other speakers. All 
speakers are unmuted, so speakers can talk freely during the session. 
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11 Cheng Wang 
12 Chiara Riganti 
13 Christina Stuelten 
14 Christina Voelkel-Johnson 
15 Dan Cojoc 
16 David Hecht 
17 David Schaffer 
18 Devyn M. Smith 
19 Dorit Ron 
20 Erik Wiemer  
21 Fanglin Zhang 
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23 Fumiyo Ikeda 
24 Gangadhara Reddy Sareddy 
25 Giulia Grisendi 
26 Iulia M. Lazar 
27 Jamil Talukder 
28 Jianjun Sun 
29 John Lyssand 
30 Jong Hyun Ham 
31 Joseph Fomusi Ndisang 
32 Juan Ding 
33 Juntang Lin 
34 Kathleen L. Hefferon 
35 Kenneth B. Storey 
36 Kevin Pfleger 
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38 Kotb Abdelmohsen 
39 Lilian I. Plotkin 
40 Lynne-Marie Postovit 
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44 Mine Erguven 
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1. Tumor-stromal crosstalk in pancreatic cancer pathobiology and chemoresistance. 
Ajay Singh, Department of Oncologic Sciences, Mitchell Cancer Institute, University of 
South Alabama, USA.  
Summary: Pancreatic cancer remains a therapeutic challenge for clinicians and 
translational researchers. Currently, it is the fourth leading cause of cancer-related death 
with a rising incidence and unabated mortality. To change this grim scenario, we need to 
develop an improved understanding of the mechanisms underlying the aggressive and 
drug-resistant nature of pancreatic cancer. In this regard, we have identified signaling 
pathways that operate through tumor-stromal interaction and mutually promote growth 
and chemoresistance of pancreatic cancer. Research is currently ongoing to 
systematically investigate the therapeutic significance of our observations with a hope 
that, in due course, it will open up new avenues for effective therapeutic care of 
pancreatic cancer patients. 
 
2. Genetic polymorphism of milk proteins and their relationship with milk 
compositional traits in Indian goat breeds.  
Ajoy Mandal, Eastern Regional Station, National Dairy Research Institute, A-12 Block, 
Kalyani- 7412 35, Nadia, West Bengal, India.  
Summary: Genetic polymorphisms of milk proteins have received considerable research 
interests because of possible associations between milk protein genotypes and 
economically important traits in dairy animals. Genetic polymorphism of milk proteins 
and their effect on milk composition traits of Indian goat breeds belonging to different 
agro-climatic regions of India was studied. Milk protein genotyping was carried out by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS – PAGE) method at 
αS1- CN (CSN1S1), β-CN (CSN2), αS2- CN (CSN1S2), κ –CN (CSN3), β-LG and α-LA 
loci. Milk proteins of different Indian goat breeds viz. Jamunapari, Barbari, Marwari, 
Sirohi, Jakhrana, Kutchi, Beetal, Ganjam and local goats, contained the four major casein 
variants i.e. αS1, αS2, β and κ and two types of whey proteins, α-lactalbumin and β-
lactoglobulin. Indian goats exhibited αS1- casein A allele in higher frequency in the 
majority of the breeds except Ganjam and local goats. A total of 16 casein haplotypes 
were observed in Indian goat breeds and breed specific haplotypes were observed with 
respect to geographical region. Expected heterozygosity at six different loci demonstrated 
the genetic diversity and breed differentiation among Indian goat breeds. The variability 
among goat breeds contributed by αS2- CN (CSN1S2), β-LG and αS1- CN. The Indian 
goats exhibited αS1- casein A allele in higher frequency in all the breeds indicating the 
higher casein yield in their milk.   
 
3. Anti-inflammatory effects of natural extracts enriched with bioactives.  
Alexander Gosslau, Department of Chemistry and Chemical Biology, Rutgers University, 
USA.  
Summary: Chronic inflammation is widely recognized as a major underlying cause of 
various degenerative diseases including diabetes, arthritis and cancer. Accumulative 
effects of tissue destruction caused by electrophilic species coupled with damage induced 
by proteolytic metalloproteinases lead to pathological conditions which increase with 
aging. The need for anti-inflammatory therapies is evident and natural products have the 
potential to fill this therapeutic gap addressing the complexity in the inflammatory 
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cascade thereby reducing side effects and compensatory reactions requiring secondary 
treatment. We developed two proprietary extracts such as black tea extract (BTE) 
enriched with theaflavins and orange peel extract (OPE) enriched with 
polymethoxyflavones. Effects on inflammation were analyzed by nutrigenomics using a 
human cell-based TPA-induced monocyte-macrophage differentiation model. BTE and 
OPE significantly down-regulated the expression of a panel of surrogate genes involved 
in inflammatory response, including COX-2, TNF- - - -6, and 
IL-8 with an inflammatory index of -0.39 and -0.55 for BTE and OPE, respectively. 
Down-regulation of inflammatory genes correlated to anti-inflammatory effects of BTE 
and OPE in different in vivo animal models for inflammation such as skin, ear, and paw 
edema. In two double blind, randomized, placebo-controlled clinical pilot trials 
employing LPS-mediated irritation or intensive exercise-induced inflammation, BTE 
induced attenuation of different cytokines and chemokines as well as reduced 
inflammatory symptoms such as ROS reduction and delayed onset muscle soreness. In 
summary, enrichment of phyto extracts such BTE and OPE with specific anti-
inflammatory bioactives is a promising strategy to find naturally derived extracts 
effective against diseases associated with inflammation. 
 
4. Slow Regulated Release of H2S Inhibits Oxidative Stress Induced Cell Death by 
Influencing Certain Key Signaling Molecules. 
Aman Shah Abdul Majid, Department of Integrative Medicine, Advanced Medical and 
Dental Institute, USM, Penang, Malaysia. 
Summary: Hydrogen sulphide (H2S) is one of three gaseous signaling molecules after 
nitric oxide and carbon monoxide. Various H2S donor compounds have been synthesized 
to study its physiological function. Among these compounds sodium hydrosulphide 
(NaHS), a donor of releasing H2S rapidly have shown to be protective in certain neuronal 
cell line but several in vivo studies have generated conflicting data. Furthermore several 
slow releasing H2S donors have been shown to have positive effects on cells in culture. 
The intracellular concentration of H2S and hence its rate of production may be a factor in 
keeping the balance between its neuroprotective and toxic effects. The present study was 
undertaken to deduce how a rapid releasing H2S donor (NaHS) as opposed to a slow 
releasing donor (ADTOH), affect oxidative stress related intracellular components and 
survival of RGC-5 cells. It was concluded that when RGC-5 cells are exposed to the toxic 
effects of glutamate in combination with buthionine sulfoxime (Glu/BSO), ADTOH was 
more efficacious in inhibiting apoptosis, scavenging reactive oxygen species (ROS), 
stimulation of glutathione (GSH) and gluthathione-S-transferase (GST). Western blot and 
qPCR analysis showed ADTOH increased the levels of Nrf2, HO-1, PKCα, p-Akt, Bcl-2 
and XIAP but caused a decrease of Nfκβ and xCT greater than NaHS. This study is first 
to compare the efficacy of two H2S donor drugs as potential neuroprotectants and 
demonstrate that slow regulated release of H2S to cell culture can be more beneficial in 
inhibiting oxidative stress induced cell death. 
 
5. From molecules to genes.  
Amol Patil, Dept. of Orthodontics and Dentofacial Orthopedics, Bharati Vidyapeeth 
Dental College and Hospital, Bharati Vidyapeeth Deemed University, Pune, 
Maharashtra, India.  
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Summary: Pending. 
 
6. Regulation of Tissue Factor biology via microRNAs.  
Andreas Eisenreich, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, 
Centrum für Herz- und Kreislaufmedizin, 12200 Berlin, Germany.  
Summary: Tissue Factor (TF) is important for the control of several physiologic and 
patho-physiologic processes, such as thrombogenesis, angiogenesis, and tumorigenesis. 
Due to the important (patho-)physiologic-relevant role of TF, the expression and  
biologic function of TF is highly regulated. In recent years, micro (mi)RNAs were shown 
to be crucial for post-transcriptional expression regulation and functional modulation of 
TF under physiologic- and patho-physiologic conditions. Here, the latest findings 
regarding the impact of miRNA on TF biology will be summarized in the context 
physiologic as well as patho-physiologic-relevant settings, such as vascular haemostasis 
control or cancer biology. 
 
7. Methamphetamine increases the levels of dopamine D2 receptor and dopamine 
transporter in dopaminergic nerve terminals.  
Anna Moszczynska, Department of Pharmaceutical Sciences, Rm 3142, Eugene 
Applebaum College of Pharmacy and Health Sciences, Wayne State University, USA.  
Summary: Methamphetamine (METH) is a central nervous system psychostimulant with 
a high potential for abuse. At high doses, METH causes a selective degeneration of 
dopaminergic terminals in the striatum. Dopamine D2 receptor antagonists and dopamine 
transporter (DAT) inhibitors protect against neurotoxicity of the drug by decreasing 
intracellular dopamine content and, consequently, dopamine autoxidation and production 
of reactive oxygen species.  In vitro and ex vivo, amphetamines regulate D2 receptor and 
DAT functions via regulation of their intracellular trafficking. Limited data exists on 
trafficking of both proteins and their protein-protein interactions in vivo.  The aim of the 
present investigation was to examine synaptosomal levels of D2 receptor and DAT after 
two different regimens of METH and to determine whether METH affects D2 receptor-
DAT protein-protein interaction in rat striatum. We report that the immunoreactivity of 
the DAT is rapidly increased by a non-toxic single dose of METH whereas the 
immunoreactivity of D2S receptor is increased by neurotoxic binge METH 
administration. Single non-toxic METH does not have much effect on D2 receptor-DAT 
protein-protein interaction whereas toxic METH increases the interaction between the 
two proteins. Our results suggest that METH can affect axonal transport of both the D2S 
and DAT in protein-protein interaction-dependent and –independent manner. 
 
8. Indexing Chemicals for their Bioactivity on GPCRs by Ligand-Structural 
Combined Approach.   
Anwar Rayan, the Drug Discovery Informatics Lab at the QRC research center – Al 
Qasemi Academic College & GeneArrest LTD company, Israel. 
Summary: Human G-Protein Coupled Receptors cover the most prominent family of 
validated drug targets. More than 50% of approved drugs reveal their therapeutic effects 
by targeting this family. In this talk, we will describe how sequential combination of 
ligand-based chemoinformatics techniques with structure-based bioinformatics 
techniques has the potential to improve the success rate in discovering new biologically 
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active compounds and increase the enrichment factors in a synergistic manner. Ligand-
based chemoinformatics technique: Two ligand-based chemoinformatics techniques, the 
Intelligent Learning Engine and Iterative Stochastic Elimination approach, were utilized 
to index chemicals for their molecular bioactivity. Structure-based bioinformatics 
technique: 3-D structure prediction of hGPCRs remains a challenge due to limited 
availability of resolved structure. The X-ray structures have been solved for only few 
receptors. The identity between hGPCRs and the potential templates is mostly less than 
30%, well below the level at which sequence alignment can be done regularly and highly 
accurate models could be obtained. We will present our findings from analysis of a large 
set of comparative models as well as a large database of family-A human G-protein 
coupled receptors and suggest few tips for improving the quality of hGPCRs homology-
based models. Acknowledgements: A.R is a management committee member of COST 
Action CM1207 titled "GLISTEN: GPCR-Ligand Interactions, Structures, and 
Transmembrane Signalling: a European Research Network". 
 
9. Limbal Side Population cells for the treatment of limbal stem cell deficiency.   
Bakiah Shaharuddin1,2, Sajjad Ahmad3,4, Simi Ali5, Annette Meeson1, 1 Institute of 
Genetic Medicine, Newcastle University, Newcastle Upon-Tyne, NE1 3BZ, UK. 2 
Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200 Pulau Pinang, 
Malaysia.3 St Paul's Eye Unit, Royal Liverpool University Hospital, Prescot Street, 
Liverpool, L7 8XP, UK.4 Department of Eye and Vision Sciences, Institute of Ageing and 
Chronic Disease, University of Liverpool, 4th Floor UCD Building, Daulby Street, 
Liverpool, L69 3GA, UK. 5 Institute of Cellular Medicine, Newcastle University, 
Newcastle Upon-Tyne, NE1 7RU, UK.  
Summary: Introduction: Limbal stem cell deficiency refers to a condition caused by 
abnormal maintenance of the limbal stem cells. Ex vivo expanded limbal epithelial stem 
cell transplantation is a contemporary cellular-based therapy to regenerate and reconstruct 
the ocular surface as a mode of treatment. The challenges in limbal stem cell biology 
remain in the process of identification, isolation and expansion of these adult corneal 
epithelial stem cells. The side population assay (SP) is an isolation method that utilises 
the ability of stem cells to efflux the DNA-binding dye Hoechst 33342 (or other vital 
dyes) combined with dual wavelength flow cytometry. Materials and Methods: Human 
cadaveric limbal tissue and human telomerase-immortalised corneal epithelial cells 
(HTCEC) were used for characterisation of cell populations of interest by PCR, flow 
cytometry and immuno fluorescence. Using an optimised limbal SP protocol we sorted 
SP and NSP cells of the HTCEC directly onto slides and stained them with antibodies to 
ABCG2, ΔNp63 and Sox2. Using Image J software combined with microscopy, the 
signal intensity for each marker was quantified. Results: Side population assay has been 
used to successfully identify stem/ progenitor cell populations in a variety of tissues and 
cell lines. We optimise this assay to identify SP cell populations in both primary human 
limbal epithelial cultures and in an established human corneal epithelial cell line. The 
limbal SP fraction showed higher expression compared to non-SP cells (NSP); ABCG2 
expression (P= 0.026), ΔNp63 (P=0.007) and Sox2 (P=0.021). Discussion and 
Conclusions: We show that SP cells isolated from the HTCEC  line using this protocol, 
have significantly elevated expression  of ABCG2, ΔNp63 and Sox2 above that displayed 
by the NSP cell fraction, supporting the use of this protocol for identification and 
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separation of a stem cell enriched cell fraction of limbal cells. In addition, the sensitivity 
of the assay to different species and cell types also makes standardisation of SP protocols 
mandatory to ensure reliability and reproducibility of SP data. Future work involves 
further characterisation of by quantitative polymerase chain reaction or proliferation 
studies such as colony forming efficiency or spheroid formation of the limbal SP. 
References: 1, Goodell, M., et al., (1996). Isolation and functional properties of murine 
hematopoietic stem cells that are replicating in vivo. J Exp Med., 183(4), 1797-1806. 2, 
Budak, M.T., et al., (2005). Ocular surface epithelia contain ABCG2-dependent side 
population cells exhibiting features associated with stem cells. J Cell Sci, 118(Pt 8), 
1715-24. 3, de Paiva, C.S., et al., (2005). ABCG2 Transporter Identifies a Population of 
Clonogenic Human Limbal Epithelial Cells. Stem Cells, 23(1), 63-73. Acknowledgment: 
Supported by grants from the Ministry of Higher Education, Malaysia and partially by 
Universiti Sains Malaysia, Pulau Pinang, Malaysia.  
 
10. ß-phenylethylamine as a novel inhibitor of E. coli biofilm.  
1Birgit M. Prüß, 1Meredith Irsfeld, and 2Shane J. Stafslien 1Department of Veterinary 
and Microbiological Sciences, North Dakota State University, Fargo ND; 2Center for 
Nanoscale Science and Engineering, North Dakota State University, Fargo ND, USA.  
Summary: A random screen of 95 carbon and 95 nitrogen sources had previously 
determined that ß-phenylethylamine (PEA) performed best at reducing bacterial cell 
counts and biofilm amounts of E. coli O157:H7 that was grown in liquid beef broth 
medium at 10oC (Lynnes et al., Meat Science, 2013). In addition, PEA reduced bacterial 
cell counts when the bacteria were grown on small pieces of beef meat. PEA is a trace 
substance in chocolate that is sold in health stores to aid weight loss and mood 
improvement. It is generally regarded as safe (GRAS status). Our two long-term goals are 
to i) develop PEA into a spray that reduces bacteria on beef meat and to ii) integrate PEA 
into novel biomaterials that inhibit biofilm formation. Working towards the second of 
these goals, we used E. coli K-12 as a model bacterium and tested the effect of PEA on 
bacterial growth (as OD600), biofilm amounts (as OD600 of the washed and resuspended 
biofilm), expression of flhD (as fluorescence from flhD::gfp), bacterial cell counts (from 
plating serial dilutions onto LB agar plates), and stability of the biofilm (with a custom 
build water jet). FlhD is part of the FlhD/FlhC transcriptional activator complex that is 
responsible for the expression of all other flagellar genes. Since flagella mediate the first 
stage of attachment, reversible attachment, an inhibition of flhD would be indicative of a 
shut down of the initial stage of biofilm formation. The water jet has been developed by 
the Center for Nanoscale Science and Engineering for the measurement of attachment 
strength of numerous marine bacteria (Stafslien et al., Rev. Scientif. Instrum., 2007). The 
technique involves a spinning head that applies a controlled water pressure to the biofilm. 
The protocol was modified to the purpose of this experiment, which also involved a 
control mutation in argD that was not expected to impact E. coli biofilm. The experiment 
revealed that bacterial growth and cell counts were not impacted by PEA until a 
concentration of 20 to 40 mg/ml was reached. In contrast, flhD expression was already 
much reduced at 0.25 mg/ml. Biofilm amounts were much inhibited at a PEA 
concentration of 6 mg/ml. Our current hypothesis is that biofilm is inhibited by PEA at its 
very onset through inhibition of flagella expression and synthesis. The determination of 
biofilm stability led to an intriguing result. Until 2 mg/ml, increasing concentrations of 
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PEA actually increased the stability of the biofilm. We conclude from this part of the 
experiment that PEA does indeed reduce biofilm amounts. However, the remaining 
bacteria appear very tightly attached to the respective surface. In contrast, a mutant in 
fliA, which also can not synthesize flagella, exhibited increased biofilm removal and 
decreased biofilm amounts after treatment with the water jet, when compared to the 
isogenic parent strain. This indicates that flagella are not just important for starting the 
biofilm, but also contribute to its integrity. In summary, we found that PEA was indeed 
an inhibitor of E. coli biofilm, likely through inhibition of flhD expression and flagella 
synthesis. In the future, we like to use this protocol to test the effect of PEA on numerous 
bacterial pathogens with the ultimate goal to integrate it into novel biofilm inhibiting 
biomaterials. 
 
11. Neural Stem Cell Models & Potential Anesthetic-Induced Neurotoxicity.  
C Wang*, F Liu, TA Patterson, MG Paule and W Slikker Jr.  Division of 
Neurotoxicology, National Center for Toxicological Research (NCTR)/FDA, Jefferson, 
AR 72079, USA.   
Summary: It is known that the most frequently used general anesthetics have either N-
methyl-D-Aspartate (NMDA)-type glutamate receptor blocking or GABA receptor 
enhancing properties. Both propofol (GABA agonist) and ketamine (NMDA antagonist) 
are widely used in pediatric anesthesia or analgesia. To evaluate their potential for 
producing developmental neurotoxicity and elucidating these underlying mechanisms, 
embryonic neural stem cells (NSCs) were used. NSCs were harvested from gestational 
day 14 rat fetuses; on day 7 in culture NSCs were exposed to 10, 50, 100, 300 and 600 
µM propofol or 1, 10, 100, and 500 µM ketamine in growth medium (GM) for 24 h 
individually; or 50 µM propofol and 10 µM ketamine in differentiation medium (DM), 
respectively. In GM propofol caused a dose-dependent reduction of NSC viability (MTT-
uptake); while ketamine did not have this effect except at 500 µM, an extremely high 
concentration. At clinically-relevant concentrations in GM, propofol (50 µM) produced a 
dramatic increase in ROS generation and enhanced apoptosis as evidenced by an 
increased number of TUNEL-positive cells and Bax (a pro-apoptotic gene) expression, 
indicating propofol-induced NSC apoptosis may be mediated by oxidative stress, while 
similar apoptotic effects were not observed when NSCs were exposed to a clinically-
relevant dose of ketamine (10 µM). No significant intracellular calcium influx was 
detected when NSCs were stimulated with 50 µM NMDA, suggesting no functional 
NMDA receptors expressed on NSCs (in GM). On the other hand, most of the NSCs 
differentiated into neurons and glial cells in the DM (with serum). Differentiated neurons 
were characterized by immunocytochemical staining of PSA-NCAM (a neuron-specific 
marker) and an apparent calcium influx stimulated with 50 µM NMDA, suggesting the 
existence of functional NMDA receptors. Propofol (50 µM) and ketamine (10 µM) 
significantly increased ROS generation in DM. Also, propofol and ketamine exposure 
specifically caused neuronal damage (neuron population; PSA-NCAM positive), while 
glial cells, e.g., astrocytes (GFAP positive) were not significantly affected in DM. 
Additionally, propofol, but not ketamine, produced a significantly higher amount of 
glutamate release from neurons (pre-synaptic) compared with control in DM. These 
observations demonstrate ROS plays a key role in propofol- or ketamine-induced 
neuronal damage. Therefore, calcium imaging, gene and protein arrays will be critical for 
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further mechanistic studies. In summary, an excitatory action of glutamate 
neurotransmission could be closely related to anesthetic-induced toxicity during 
development. Supported by NCTR/FDA E-7417.  
 
12. NO-releasing doxorubicins: new anthracycline derivatives that overcomes drug-
resistance in cancer cells.  
Chiara Riganti, Biochemistry, Department of Oncology, Turin School of Medicine, 
University of Turin, Italy.  
Summary: The major limitations of doxorubicin (DOX) are the onset of drug resistance 
and the cardiotoxicity. In previous studies we have shown that nitric oxide (NO) donors 
associated with DOX overcome the resistance. NO can nitrate critical tyrosines on ATP-
binding cassette (ABC) transporters, such as P-glycoprotein (Pgp/ABCB1), multidrug 
resistance related proteins (MRPs/ABCCs) and breast cancer resistance protein 
(BCRP/ABCG2). Following the nitration, the activity of ABC transporters was inhibited 
and DOX was less effluxed [1]. In order to improve the effects of NO in reversing drug 
resistance, we designed new polyvalent drugs that were at the same time anti-cancer 
agents and NO-delivery systems. We produced synthetic DOXs conjugated with NO-
releasing groups, namely nitrooxy-DOX (NitDOX) and 3-phenylsulfonylfuroxan-DOX 
(FurDOX) [2]. We tested them in a panel of human drug-sensitive and drug-resistant 
cancer cells, created by selecting the parental cell lines in a DOX-containing medium. 
Nit-DOX and Fur-DOX released NO in a dose- and time-dependent manner, nitrated 
ABC transporters, were more accumulated than DOX and had a lower IC50 than DOX in 
all the drug-resistant cells analyzed. Nit-DOX was not more cytotoxic than DOX in 
cardiomyocytes and in non transformed epithelial cells in vitro, and was further 
investigated. Surprisingly NitDOX showed properties far different from a typical 
anthracycline: it did not inhibit the purified topoisomerase II enzyme, it was uptaken with 
a faster kinetics, it produced different metabolites, it showed an extranuclear distribution 
and a preferential accumulation in mitochondria. The mitochondrial delivery was due to 
the higher hydrophobicity and to the lower efflux of NitDOX, which nitrated and 
inhibited MRP1 and BCRP present in mitochondrial membranes. In mitochondria 
NitDOX inhibited the tricarboxylic acid cycle, the electron flux through Complex I and 
the synthesis of ATP, induced the release of cytochrome c in the cytosol and the 
activation of caspase-9-dependent apoptosis. All these events were dependent on the 
release of NO, since they were reduced by NO scavengers. Of note, the effects on 
mitochondrial metabolism and apoptosis were equally achieved in drug-sensitive and 
drug-resistant cells [3]. We propose nitrooxy-doxorubicin as the first lead compound of a 
new series of polyvalent anthracyclines, characterized by different mechanisms from 
traditional anthracyclines and able to overcome drug resistance. References [1] Riganti C, 
Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A (2005). Nitric 
oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the 
drug efflux. Cancer Res 65: 516-525; [2] Chegaev K, Riganti C, Lazzarato L, Rolando B, 
Guglielmo S, Campia I, Fruttero R, Bosia A, Gasco A (2011). Nitric oxide donor – 
doxorubicin conjugates accumulate into doxorubicin resistant human colon cancer cells 
inducing cytotoxicity. ACS Med Chem Lett 2:494-497; [3] Riganti C, Rolando B, 
Kopecka J, Campia I, Chegaev K, Lazzarato L, Federico A, Fruttero R, Ghigo D (2013). 
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Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug 
resistance. Mol Pharm 10:161-174. 
 
13. Cell Directionality as an Indicator of Breast Cancer Progression.  
Christina H. Stuelten, Rachel M. Lee, Michael Weiger, Lunhua Liu, Wolfgang Losert, 
and Carole A. Parent, Cell and Cancer Biology Branch, National Cancer Institute, USA.  
Summary:  During malignant progression, epithelial tumor cells invade surrounding 
healthy tissues and migrate to metastatic sites.  Therefore, tumor cell invasion and spread 
represent key targets to control tumor disease.  However, little is known about tumor cell 
migration during malignant progression.  Using a series of genetically related breast 
cancer cell lines, MCF10A, MCF10At.1k, MCF10CA1h, MCF10CA1a, and MDA-MB-
231T cells we can show that migratory speed as well as distance traveled does not 
distinguish invasive and metastatic cells from normal epithelia cells in established assays 
such as wound healing assays or Boyden chamber assays.  However, more detailed 
analysis of migration of cell sheets by time-lapse imaging and subsequent particle image 
velocimetry (PIV) revealed that invasive cell lines migrated in a more random, less 
directional motion.  Epithelial growth factor (EGF) and lysophosphatidic acid (LAP) 
which both have been implicated in tumorigenesis and tumor progression, exhibited 
distinct effects on the migratory phenotype of the investigated breast cancer cell line.  
Interestingly, LPA reverted the migratory pattern of invasive MCF10CA1a cells to a 
pattern similar to that observed in normal epithelial MCF10A cells, as it caused 
MCF10CA1 cells to migrate in a more orderly and directed pattern. Currently, we 
investigate the effects of LPA on the migratory phenotype as well as E-cadherin- and 
myosinIIb expression patterns in our model system. 
 
14. Sphingosine kinase 2 as a novel therapeutic target in prostate cancer.   
Helen Gosnell*, Laura M. Kasman*, Lucas Vu*,Thrimoorthy Potta**, Elizabeth Garrett 
Mayer*, Kaushal Rege**, and Christina Voelkel-Johnson *. *Department of 
Microbiology and Immunology, Medical University of South Carolina, Charleston SC 
and **Department of Chemical Engineering, Arizona State University, Tempe, AZ, USA. 
Heather Venant 1, Charles D. Smith 2, Michael Lilly3, and Christina Voelkel-Johnson 1 
1 Department of Microbiology and Immunology, Medical University of South Carolina, 
Charleston, SC, USA; 2 Department of Drug Discovery and Biomedical Sciences, 
Medical University of South Carolina, Charleston, SC, USA and Apogee Biotech 
Corporation, Hummelstown PA, USA; 3 Department of Medicine, Medical University of 
South Carolina, Charleston, SC, USA.  
Summary: The development of castration resistant prostate cancer (CRPC) and lack of 
effective therapies to treat this disease remain major clinical obstacles. Curative options 
are lacking and even novel therapy approaches, such as the androgen receptor inhibitor 
enzalutamide, prolong survival only by approximately 4-5 months. In recent years, 
evidence that inflammation promotes tumor growth has been mounting and levels of 
inflammatory cytokines correlate with the extent of the disease in prostate cancer 
patients. Sphingosine-1-phosphate (S1P) is an important lipid mediator that has been 
shown to play roles in survival, drug resistance, angiogenesis and inflammation. 
Consequently, S1P as well as the enzymes responsible for its production (sphingosine 
kinase 1 and 2) have evolved as important therapeutic targets. A small study using human 
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tumor cDNA arrays revealed that SphK2 but not SK1 expression was markedly elevated 
in prostate tumors compared to normal prostate tissue. In situ analysis of existing 
microarray data from patient matched normal and malignant prostate tissue indicates that 
SphK2 mRNA is upregulated in nearly half of the prostate cancers. Further, analysis of a 
prostate tissue microarray reveals that SphK2 is expressed in the prostate but that 
infiltrating inflammatory cells stain the strongest for this enzyme. A novel, first-in-class 
SphK2-selective inhibitor ABC294640 is currently under evaluation in a phase I clinical 
trial. In preclinical models, this drug was found to exert anti-proliferative and anti-
inflammatory effects. We are currently evaluating the impact of SphK2 inhibition in 
prostate cancer, both alone and in combination with androgen blockade. This study may 
establish the foundation for novel combination therapies of advanced prostate cancer. 
 
15. Focal stimulation of neuronal cells by optical manipulation.  
Dan Cojoc, IOM-CNR, Institute of Materials- National Research Council, Italy.  
Summary: Spatial regulation of secretory molecule release is a sophisticated mechanism 
used by the nervous system to control network development and finely tune the activity 
of each synapse. Great efforts have been made to develop techniques that mimic 
secretory molecule release with the aim of stimulating neurons as close as possible to 
physiological conditions. However, current techniques have poor spatial resolution or low 
flexibility. Here, we propose a novel approach to achieve focal stimulation of neurons by 
optical trapping and manipulation of micro-vectors carrying signaling molecules. We 
discuss two examples of vectors: microbeads functionalized with a secretory molecule, 
the neurotrophin brain-derived neurotrophic factor (BDNF) and liposomes encapsulating. 
guidance molecules Sema3A and Netrin-1. In the first example we show that single 
BDNF-coated microbeads can be optically manipulated from small reservoirs to specific 
sites on the dendrites of cultured hippocampal neurons. Localized contact of the BDNF 
microbead induced an increase of calcium signaling both in the soma and in the 
stimulated dendrite. It induced also a specific activation of the TrkB receptor pathway 
and influenced the development of growth cones. Remarkably, a single BDNF-coated 
bead localized on a dendrite was found to be enough for TrkB phosphorylation, an 
efficient and long-lasting activation of calcium signaling in the soma, and c-Fos signaling 
in the nucleus, comparable to bath stimulation conditions [1]. In the second example we 
discuss another type of vector, lipid vesicles, to encapsulate guidance cues. It is known 
that growth cones (GCs) are the major motile structures guiding neuronal navigation and 
guidance molecules, such as Sema3A or Netrin-1, induce GC repulsion or attraction. 
Nevertheless, the speed of action and efficiency of these guidance molecules is still 
poorly understood, requiring a local delivery and a strict control of the amount of 
molecules released. Therefore we developed an experimental setup based on optical 
manipulation techniques (i.e. optical tweezers and UV micro-dissection) to deliver 
controlled amounts of these molecules specifically to GCs [2]. Lipid microvesicles were 
used as vectors for the encapsulation of the guidance cues. By means of an IR-optical 
tweezers, single vesicles were selected, trapped and positioned to the site of stimulation 
nearby the GC. Vesicles were then broken by UV a laser pulse to release the content. 
Sema-3A and Netrin-1 molecules were delivered to single growth cones in hippocampal 
neuronal cultures, and morphological modifications of growth cones in response to the 
release were monitored in time lapse imaging. The amount of molecules delivered was 
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calculated considering the volume of the vesicle, the concentration of the signaling 
molecules in solution and the encapsulation efficiency. A wide range (10 to 104 
molecules per vesicle) could thus be investigated. After their release the guidance 
molecules diffused and reached the GC membrane in a few seconds. Following their 
arrival GCs retracted or grew in less than 2 min. By determining the number of guidance 
molecules trapped inside vesicles and estimating the fraction of guidance molecules 
reaching the GC, we show that less than 5 Netrin-1 molecules on the GC membrane are 
sufficient to induce growth. In contrast, more than 200 Sema3A molecules is necessary to 
induce filopodia retraction. Our results show that optical manipulation techniques open 
new opportunities to investigate signal transduction mechanisms. References: 1. E. 
D’Este, G. Baj, P. Beuzer, E. Ferrari, G. Pinato, E. Tongiorgi, and D. Cojoc, “Use of 
optical tweezers technology for long-term, focal stimulation of specific subcellular 
neuronal compartments”, Integr. Biol. 3, 568 (2011). 2. G. Pinato, T. Raffaelli, E. D’Este, 
F. Tavano, and D. Cojoc D (2011), “Optical delivery of liposome encapsulated chemical 
stimuli to neuronal cells”, J Biomed Opt, 16:095001 (2011).  3. G. Pinato, D. Cojoc, L. 
Thuy Lien, A. Ansuini, J. Ban, E. D’Este, and V. Torre, "Less than 5 Netrin-1 molecules 
initiate attraction but 200 Sema3A molecules are necessary for repulsion," Sci. Rep. 2, 
675 (2012). 
 
16. Modeling the Evolution of Drug Resistance in Malaria.  
David Hecht, Chemistry at Southwestern College in Chula Vista, California and an 
adjunct faculty member, San Diego State University Dept. of Chemistry, USA.  
Summary: The evolution of drug resistance in malaria continues to be a widespread 
concern. Many of these drugs target key proteins such as dihydrofolate reductase 
(DHFR). However in malaria, the structural plasticity of DHFR allows it to maintain its 
active site and catalytic activity, while resisting drug binding. One way to better 
understand this process is through the appreciation of DHFR structural evolution in 
general, and then use in silico evolution to model both the drug docking and the likely 
amino acid changes in DHFR that will occur as a result. Here we study the amino acid 
replacements in dihydrofolate reductase (DHFR) that confer resistance to anti-folate 
drugs while still binding the natural DHFR substrate, 7,8-dihydrofolate, and cofactor, 
NADPH. Iteration of this process allows the opportunity to model the coevolutionary 
processes involved with drug resistance and to predict responses to pharmaceuticals in 
advance of their use in the field. 
 
17. Molecular Elucidation and Engineering of the Stem Cell Fate Decisions.  
David Schaffer, Chemical and Biomolecular Engineering, Bioengineering, and the Helen 
Wills Neuroscience Institute, Berkeley Stem Cell Center, University of California, 
Berkeley, CA, USA, 94720-3220.  
Summary: Elucidating the mechanisms that govern stem cell self-renewal and 
differentiation is critical for understanding the roles these cells play in organismal 
development and function as well as for harnessing stem cells to repair tissues damaged 
by disease or injury.  It has become increasingly clear that stem cells are regulated not 
only by biochemical signals in the niche, but also by biophysical features in the way these 
signals are presented, though investigating the latter is challenged by experimental 
complexities in investigating and mimicking the complexity of the extracellular matrix 
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(ECM), cell-cell interactions, and other niche components.  Recent work has 
demonstrated that bioactive, synthetic materials can be harnessed to emulate and thereby 
study the effects of solid phase, biophysical cues on cell function.  For example, 
activation of many cellular receptors involves the formation of oligomeric protein 
signaling complexes with ligands presented from the matrix, the surface of neighboring 
cells, and in some cases even from solution.  We have developed multivalent ligands – 
polymers conjugated to signaling proteins to yield biomimetic signals with nanoscale 
spatial organization – which potently induce the differentiation of human pluripotent 
stem cells in vitro and neural stem cells in vitro and in vivo.  In addition, these materials 
combined with optogenetics and super-resolution microscopy have yielded insights into 
signaling mechanisms that regulate the fate decisions of these cells.  Finally, such 
biomimetic materials can be integrated into safe, scaleable, and robust bioprocesses for 
pluripotent stem cell expansion and differentiation. 
 
18. Leveraging stem cell discoveries to enable drug discovery?  
Devyn M. Smith, Pfizer's Neusentis Research Unit, USA.  
Summary: Big pharma has been attempting to improve the pace and rate of new drug 
discovery over the last decade.  Many different approaches have been used to improve 
R&D productivity.  Stem cells provide a unique opportunity to potentially improve 
overall R&D productivity and many companies are testing this hypothesis.  There are a 
few key areas where Pharma are using stem cells in their traditional R&D work.  These 
areas include:  generating early data on efficacy and safety of compounds, using stem 
cells to create better assays for high throughput screening of traditional libraries, and use 
of stem cells to enable better translation from pre-clinical to clinical data.  We will 
discuss where iPS cells can enable pharmaceutical R&D and give specific examples to 
illustrate the work ongoing in Pharma. 
 
19. Presentation Title: Signaling Mechanisms Underlying Alcohol Abuse Disorders. 
Dorit Ron, Cell Biology of Addiction in Neurology, Department of Neurology, University 
of California, San Francisco, Gallo Research Center Investigator, USA.  
Summary: Pending. 
 
20. MicroRNAs in the tumor biology of soft tissue sarcomas.  
Caroline M.M. Gits, Stefan Sleijfer, Erik A.C. Wiemer, Department of Medical Oncology, 
Erasmus University Medical Center – Erasmus MC Cancer Institute, Rotterdam, the 
Netherlands. 
Summary: Sarcomas are relatively rare tumors of mesenchymal origin that comprise 
about 1% of all adult malignancies. They constitute a heterogeneous group of tumors 
consisting of more than 50 histological subtypes that can occur almost anywhere in the 
body such as in muscles, fat, bone, cartilage, fibrous tissue, synovial tissue and nerves. 
Roughly they can be classified into two large groups primary bone sarcomas and soft 
tissue sarcomas. Liposarcomas are one of the most common types of soft tissue sarcomas, 
representing approximately 10 – 15% of all mesenchymal neoplasms. They are of 
adipogenic origin and are currently classified into three major biological entities and five 
histological subtypes: differentiated/dedifferentiated, myxoid/round cell and pleomorphic 
liposarcomas. The subtypes display different biological characteristics and clinical 
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behavior. Standard treatment consists of surgery in combination with systemic 
chemotherapy, but nevertheless mortality rates are high. More insight into the biology of 
liposarcoma tumorigenesis is needed to devise novel therapeutic approaches. We 
demonstrate that miRNA expression profiling can be used to discriminate liposarcoma 
subtypes, which could aid in objective diagnostic decision making. In addition, our data 
indicate that miR-145 and miR-451 act as tumor suppressors in adipose tissue and show 
that re-expression of these miRNAs could be a promising therapeutic strategy for 
liposarcomas. Gastrointestinal stromal tumors (GIST) are the most common primary 
mesenchymal malignancies found in the gastrointestinal tract. GISTs are characterized by 
high expression of KIT and ETV1 which cooperate in GIST oncogenesis. We identified 
miRNAs that are deregulated in GIST notably miR-17-92 and miR-221/222 cluster 
members. Overexpression of these miRNAs in GIST cell lines lines severely inhibited 
cell proliferation, affected cell cycle progression, induced apoptosis and strongly 
downregulated  protein and - to a lesser extent – mRNA levels of their predicted target 
genes KIT and ETV1.  Luciferase reporter assays confirmed direct regulation of KIT and 
ETV1 by miR-222 and miR-17/20a, respectively. In conclusion our results indicate that 
miR-17/20a/222 play a role in GIST pathogenesis and may potentially be used as 
therapeutic tool. 
 
21. The inflammatory factors and their epigenetic regulation in Multiple sclerosis. 
Fanglin Zhang, Department of Neurology, Multiple Sclerosis Research Center, 
Vanderbilt University Medical Center, USA.  
Summary: Pending. 
 
22. Age-related dysfunction in mechano-transduction impairs differentiation of 
human mammary epithelial progenitors.  
Fanny Pelissier, Life Science Division, Lawrence Berkeley National Laboratory, 
Berkeley, California, USA.  
Summary: Dysfunctional progenitor cells accumulate during aging in human mammary 
epithelia, which is associated with increased cancer risk. We tested whether aging 
impaired epithelial progenitors to differentiate in response to changes in tissue 
mechanical properties. Culture substrata were tuned to mimic breast tissue elastic moduli, 
from compliant normal to stiffer malignant, to functionally probe modulus-dependent 
differentiation in primary multipotent progenitors from younger (<30yrs) and older 
(>55yrs) women. In young progenitors, compliant substrata enhanced luminal 
differentiation, whereas stiffer substrata favored myoepithelial differentiation, which 
required the YAP/TAZ transcription factors.  Older progenitors showed no differential 
responses to physiological modulus changes. Patterns of modulus-dependent actin stress-
fibers, focal-adhesions, and ERK phosphorylation were age-independent demonstrating 
that mechano-sensing was unaffected by age. YAP/TAZ activation in older progenitors 
required extra-physiological stiffness and unexpectedly caused luminal differentiation. 
Immortalization of old progenitors restored physiological YAP/TAZ activation, but 
luminal-skewed differentiation patterns persisted, congruent with durable age-related 
epigenetic alterations. Thus age-dependent accumulation of progenitors is explainable by 
inefficient transduction of pro-differentiation mechanical cues. 
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23. Sharpin plays an important role in the regulation of keratinocyte apoptosis and 
skin inflammation.  
Fumiyo Ikeda, Institute of Molecular Biotechnology (IMBA) Dr. Bohr-Gasse 3, 1030, 
Vienna, Austria.  
Summary: Sharpin is a subunit of Linear Ubiquitin chain Assembly Complex (LUBAC) 
E3 ligase complex, specifically generating linear (Met1-linked) ubiquitin chains. We 
have previously shown that Sharpin is required to fully activate the NF-kB signal induced 
by inflammatory cytokines. On the other hand, a Sharpin deficient mouse line, Cpdm 
(Chronic proliferative dermatitis mice) shows a heavy inflammatory phenotype in 
multiple organs including skin, gut and esophagus. Interestingly, a significant increase of 
apoptotic keratinocytes is observed in Cpdm. Inhibition of apoptosis by depleting TNFR1 
associated death domain protein (TRADD) in epidermal keratinocytes of Cpdm mouse 
line rescued the inflammatory phenotype in the skin. Apoptosis in mouse embryonic 
fibroblasts (MEFs) derived from Cpdm was drastically increased upon TNF-a stimulation 
in comparison to the wild type MEFs. We found that the induction of apoptosis in Cpdm 
MEFs is via the Death-inducing Signaling Complex (DISC) pathway. In addition, we 
identified that Fas-Associated protein with Death Domain (FADD) as a novel substrate of 
LUBAC and FADD ubiquitination plays a role in the Sharpin-dependent anti-apoptosis 
signaling. In conclusion, we elucidated the regulatory mechanism of Sharpin dependent 
anti-apoptosis pathway via FADD ubiquitination. Further, apoptosis of keratinocytes in 
Cpdm is one of the major causes of the skin inflammation. 
 
24. Proline Glutamic acid and Leucine rich Protein1 (PELP1) is a novel coregulator 
of β-catenin in glioblastoma.  
Gangadhara R. Sareddy and Ratna K. Vadlamudi. UTHSCSA, San Antonio, TX, USA.  
Summary: Glioblastoma (GBM) are the most common and deadliest intracranial 
neoplasms. Despite recent advances in the standard therapies, the survival of GBM 
patients is approximately 12-14 months. Better understanding of the molecular pathways 
and mechanisms that contributes to the GBM development is clinically significant and 
will provide novel therapeutic targets. In the present study, we examined the significance 
of proto-oncogene PELP1 that functions as a coregulator of many nuclear transcriptional 
factors. PELP1 expression is commonly deregulated in hormonal cancers, however, little 
is known about PELP1 and its significance in GBM. Using immunohistochemical 
analysis of glioma tissue microarrays that contain different grades of astrocytomas, 
oligodendrogliomas, ependymomas and normal brain tissues, we found that PELP1 is 
overexpressed in glioma compared to normal brain, with highest expression in GBM, and 
PELP1 expression levels were positively correlated with histological malignancy. PELP1 
expression was also found to be elevated in various established and patient derived GBM 
cells when compared to normal astrocytes. To establish the functional significance of 
PELP1 in GBM, PELP1 expression was silenced using PELP1 specific siRNA and 
shRNA. We observed that silencing of PELP1 reduced the cell proliferation, cell 
migration and colony formation of U87, T98G and LN229 GBM cells. Mechanistic 
studies showed that PELP1 interacts with β-catenin and silencing of PELP1 resulted in 
decrease in β-catenin reporter gene activation. Accordingly, PELP1 knockdown 
dramatically reduced the expression of β-catenin target genes such as Axin2, cyclin D1, 
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c-Myc and MMP-2. Chromatin-immunoprecipitation assays showed that silencing of 
PELP1 compromised the recruitment of β-catenin to the target genes promoters. In 
xenograft based tumorigenecity assays we found that silencing PELP1 dramatically 
reduced the in vivo tumor growth of U87 GBM cells. Taken together these results 
provide the first evidence that PELP1 could be a potential target for therapeutic 
intervention in GBM. 
 
25. Gene modified mesenchymal progenitor cells for cancer gene therapy.  
Giulia Grisendi, PhD & Massimo Dominici, MD, Department of Medical and Surgical 
Sciences for Children & Adults, University Hospital of Modena and Reggio Emilia, Italy.  
Summary: Despite significant advances in the field of gene therapy for cancer, the lack 
of tumor tropism of vectors and stimulation of an immune response limit the clinical 
potential of this approach. The use of mesenchymal stromal/ stem cells (MSC) as cellular 
vehicle represents an attractive option to overcome these barriers supporting targeted 
delivery of a gene or therapeutic protein to the tumor site. Thanks to their biological and 
immunological features, including easy accessibility from different source, rapid 
proliferation in culture and poor immunogenicity, MSC represent a powerful weapon to 
develop novel strategy to fight cancer. In particular the typical tropism displayed by MSC 
against tumor sites has aroused growing interest among researchers. Several studies on 
solid tumor microenvironment have indicated that MSC take active part in generation of 
a supportive stroma, becoming structural components of tumor architecture and releasing 
cytokines and chemokines at the tumor site. Based on this knowledge, we conceived to 
use modified adipose MSC as “trojan horse” to deliver an anticancer molecule against 
different tumors. We have previously demonstrated that a pro-apoptotic agent named 
tumor necrosis factor related apoptosis inducing ligand (TRAIL) can be effectively 
delivered by MSC, targeting different cancer types. More recently, we have further 
challenged our cell therapy approach based on MSC expressing TRAIL against 
mesenchymal tumors such as sarcoma. Sarcomas are a heterogeneous group of rare 
malignant tumors that arise from mesenchymal tissues such fat, bone, cartilage and 
muscle. They comprise less than 10% of all malignancies but about 15% of pediatric 
cancers. Several studies have demonstrated that TRAIL can induce cell death in a variety 
of sarcomas either alone or in concert with immunomodulation and cytotoxic therapies. 
Actually surgery, used in combination with chemotherapy and radiation therapy, 
represent the first line treatment for sarcoma, however therapies are not definitive and 
disseminated refractory diseases are associated with a reduced overall survival of less 
than 15% at 5 years. Major metastatic sites are represented by lung and, even after 
metastasectomy, the majority of patients (60%) do not survive more than 5 years. The 
poor prognosis for metastatic or tumor relapse has pointed out the needed of novel and 
more effective therapies. In this preclinical study, for the first time, we have explored the 
use of genetically modified mesenchymal progenitors expressing the anticancer molecule 
TRAIL in order to counteract these rare mesenchymal cancers. In vitro, MSC-TRAIL 
were able to induce cell death in three different sarcoma histotypes moreover, when 
injected into pre-established Ewing’s Sarcoma xenotransplants, MSC-TRAIL 
counteracted tumor development causing massive cancer apoptosis and exerting potent 
anti-angiogenic functions. Collectively, our results suggest that MSC as cellular vehicles 
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for TRAIL could open a novel therapeutic opportunity for sarcomas affecting young 
generation and still characterized by bad prognosis. 
 
26. The Role of Proteomics in the Elucidation of Cancer Pathways.   
Iulia M. Lazar,* Jingren Deng and Fumio Ikenishi, Department of Biological Sciences, 
Virginia Polytechnic Institute and State University, USA. 
Summary: The importance of advancing the frontiers of science to enable early cancer 
detection can never be over-stated. The lack of a quantitative correlation between gene 
and protein expression levels significantly impedes the identification of therapeutic 
targets and the development of novel treatment strategies for cancer. In addition, the 
laborious reconstruction and understanding of cellular signaling networks that lead to the 
progression of this disease is primarily dependent on the identification of all proteins 
expressed in a specific cell type, and their posttranslational modifications. At the present 
time, this information is incomplete. For example, reversible protein phosphorylation at 
Ser, Thr or Tyr residues, in response to external stimuli, represents a key signal 
transduction mechanism that is involved in controlling fundamental biological processes 
such as gene expression, cell cycle progression, cell proliferation, growth, differentiation, 
metabolism and apoptosis. Nevertheless, actual protein phosphorylation in a cell is not 
readily predictable by bioinformatics approaches, and experimental detection of this 
posttranslational modification is necessary. The progress in advanced technologies such 
mass spectrometry detection has enabled researchers in the past decade to generate a 
massive amount of data. The challenge, however, of making use of such data rests with 
finding a strategy to reduce the “dimension” of the findings and placing the data in the 
right biological context. In this presentation, we will describe the realm of a set of 
proteomic data generated through the analysis of three cell lines (MCF-7/ER+ cancer, 
SKBR-3/Her2+ cancer, and MCF-10 non-tumorigenic) in two different stages of the cell 
cycle, G1 and S. We will address the main sources of challenge, the computational 
techniques that are used to derive statistical significance, and the approaches that can be 
used to validate the results, enhance biological significance and improve the study design. 
Ultimately, we will discuss the pathways that were identified and matched to biological 
mechanisms that drive aberrant cancer cells into division. 
 
27. Leukotriene activates Ca2+ dependent dephosphorylation of ASCT1 to down 
regulate Ala transport in IEC-6 cells.  
Jamil Talukder, Biology, LeMoyne-Owen College, USA.  
Summary: Arachidonic acid metabolite derived via Lipoxygenase pathway, leukotriene 
D4 (LT) inhibits Na+-dependent alanine cotransport (ASCT1, solute carrier, SLC1A4) in 
intestinal epithelial cell brush border membrane (BBM) by decreasing the affinity of 
cotransporter. However, the intracellular mechanism of LT mediated inhibition of 
ASCT1 is unknown. This study was designed to investigate the intracellular mechanism 
of ASCT1 inhibition by LT in enterocytes. [3H]-Ala uptake was measured in 10 days 
postconfluent rat intestinal epithelial cells (IEC-6) grown on transwell plates. IEC-6 cells 
were treated with different inhibitors intercepting different checkpoints of pathways for 
LT mediated inhibition of ASCT1 at 8 days postconfluence. LT treatment decreased 
ASCT1 activity and increased more than 2.5-fold intracellular cAMP. However, protein 
kinase A (PKA) inhibitor did not reverse the LT mediated inhibition of ASCT1. LT 
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increased 2-fold cytosolic Ca2+ and PKC-α antagonized LT effect on ASCT1 activity. In 
contrast, PKC-δ and -θ inhibitor did not reverse LT mediated inhibition of ASCT1. 
Further downstream of PKC-α pathway, tyrosine kinase (Akt) inhibitor also reversed LT 
mediated inhibition of ASCT1 activity. Kinetics, western blotting, and qRT-PCR studies 
demonstrated that the mechanism of reversal of LT mediated inhibition of ASCT1 by Akt 
inhibitor was due to the restoration of affinity of the cotransporter. Immunocytochemical 
and dephosphorylation studies revealed that ASCT1 was dephosphorylated by LT 
treatment. Therefore, we conclude that LT inhibits ASCT1 activity by dephosphorylation 
through Ca2+-dependent PKCα-Akt pathway in enterocytes.  
 
28. Presentation Title: Pending.  
Jianjun Sun, Biological Sciences, University of Texas at El Paso, USA. 
Summary: Pending. 
  
29. Rethinking the Traditional Western.  
John Lyssand, Ph.D., Field Applications Scientist, Biotechnology, LI-COR Biosciences, 
USA.  
Summary: Traditional Western blotting is a labor-intensive process that includes gel 
electrophoresis, protein transfer to a blotting membrane, incubation with primary and 
secondary antibodies, and chemiluminescent or fluorescent detection of target proteins. 
Day-to-day reproducibility is poor, because small variations in lysate preparation, gel 
loading, electrophoresis, transfer, and detection are unavoidable sources of technical 
variability. The In-Cell Western™ (ICW) assay, a quantitative immuno-fluorescent 
method, is an alternative to traditional Western blots that increases both reproducibility 
and sample throughput. Here we describe the In-Cell Western Assay. Cells are cultured 
and treated in microplates. After treatment, cells are fixed and permeabilized, blocked, 
and incubated with antibodies for detection of target proteins. Fluorophore-coupled 
secondary antibodies and detection with a LI-COR Odyssey® imaging system enable 
superior sensitivity, accurate quantitation, and easy normalization to a loading control. 
The traditional Western blot protocol is streamlined, eliminating cell lysis, gel 
electrophoresis, and membrane transfer. The In-Cell Western assay enables screening and 
analysis of many more samples in each experiment, eliminates error-prone protocol steps, 
and delivers higher reproducibility for biological and technical replicates. Tips for 
optimization will also be discussed. 
 
30. The intercellular signaling systems for the virulence of the rice pathogenic 
bacterium Burkholderia glumae.  
Jong Hyun Ham, Department of Plant Pathology and Crop Physiology, Louisiana State 
University Agricultural Center, Baton Rouge, LA 70803, USA.  
Summary: Burkholderia glumae is the major causal agent of bacterial panicle blight, an 
emerging bacterial disease of rice. Phytotoxins, toxoflavin and its derivatives, are an 
important virulence factor of this pathogen. The quorum-sensing mediated by the LuxI 
and LuxR homologs, TofI and TofR, is known to be a central signaling/regulatory system 
for the expression of major virulence factors including toxoflavin and lipase. From our 
molecular genetic and genomic studies of B. glumae, novel signaling/regulatory 
components involved in bacterial virulence have been identified. Genetic dissection of 
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the tofI/tofR locus through a series of gene deletions revealed the new quorum-sensing 
modulator tofM located between tofI and tofR. In particular, intercellular signaling 
independent of tofI and tofR was discovered from the study of tofM. Transcriptome 
analyses through RNA-sequencing revealed genes and non-coding RNAs differentially 
expressed in tofI-dependent or tofI–independent ways in liquid and solid medium 
conditions, respectively. This transcriptome analysis also implied that DSF-type quorum-
sensing and the cyclic di-GMP signaling are under the control of (or interconnected with) 
the TofI/TofR quorum-sensing system.      
 
31. Heme oxygenase ameliorates cardiomyopathy by suppressing markers of heart 
failure and inflammation in normoglycemic obese rats".  
Joseph Fomusi Ndisang, Department of Physiology, University of Saskatchewan, 
Canada.  
Summary: Pending. 
 
32. Friend or foe: Anti-aging cosmetics on the eye.   
Juan Ding, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard 
Medical School, Boston, MA, USA.  
Summary: With a growing aging population, anti-aging cosmetics continue gaining 
popularity. However, potential concerns are raised with the main anti-aging ingredient, 
retinoic acid (RA), on the health of the eye. RA can have serious adverse effects on the 
meibomian gland, a sebaceous gland in the eye lids that secrete lipids to the tear film to 
prevent its evaporation. RA is known to cause keratinization and obstruction, gland 
atrophy, gland drop out and poor quality of meibomian gland secretions.  These signs are 
the hallmarks of meibomian gland dysfunction (MGD), a major cause of dry eye disease 
(DED) that affects hundreds of millions of people world wide. The mechanism how RA 
induces MGD is not well understood. We hypothesize that RA alters gene and protein 
expression, inhibits cell proliferation, attenuates cell survival pathways and promotes cell 
death in human meibomian gland epithelial cells. To test our hypotheses, immortalized 
human meibomian gland epithelial cells were cultured with or without RA for varying 
doses and time. Cell proliferation, cell death, gene expression, and proteins involved in 
proliferation/survival and inflammation were evaluated. We found that 13-cis RA 
inhibited cell proliferation, induced cell death, and significantly altered the expression of 
6,726 genes, including those involved in cell proliferation, cell death, differentiation, 
keratinization and inflammation, in human meibomian gland epithelial cells. Further, RA 
also reduced the phosphorylation of Akt and increased the generation of interleukin-1β 
and matrix metallopeptidase 9. Thus we have unraveled the mechanism of RA-induced 
MGD. Future studies are needed to identify molecular targets to inhibit these adverse 
actions of RA, with the ultimate goal of eliminating the dry eye inducing side effect of 
anti-aging cosmetics. [Supported by NIH grant R01EY05612 and AFER/Vistakon Dry 
Eye Fellowship] 
 
33. Pax3 and Pax7 reversely interact and regulate the expression and distribution of 
their target genes in the chicken developing spinal cord.  
Juntang Lin1,2, Congrui Wang1,2, Ciqing Yang2, Christoph Redies1 1 Institute of 
Anatomy I, University of Jena School of Medicine, Jena University Hospital, Teichgraben 
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7, D-07743 Jena, Germany; 2 Xinxiang Medical University, Jinsui Road 601, 453003 
Xinxiang, China. 
Summary: Pax3 and Pax7 both are transcription factors and widely expressed in the 
developing nervous system and somites. In the central nervous system, they both are 
expressed in the dorsal part of the neural tube. It is known that Pax3 and Pax7 are 
involved in Shh signaling pathway and inhibited by Shh over-expression. In the present 
study, we in vivo confirmed that of Pax3 over-expression represses the expression of 
Pax7, while Pax7 over-expression endogenously enhances and ectopically induces the 
expression of Pax3 in the developing chicken spinal cord. They both inhibit the 
endogenous expression of Gli1, Gli2, but induce the ectopic transcript of Gli3. To two 
members of cadherin family, Cadherin-7 and Cadherin-20, the over-expression of Pax3 
and Pax7 repress their endogenous but induce their ectopic expression which indicate a 
different regulation way from Shh signaling pathway. The down-regulation of Pax3 and 
Pax7 with specific shRNA, not their over-expression, results in apoptosis in the 
developing spinal cord, suggesting Pax3 and Pax7 are involved in cell proliferation. 
Collectively, these results suggest that transcription factor Pax3 and Pax7 play important 
roles to regulate their target genes expression/distribution and cell proliferation in the 
developing spinal cord. Key words: Pax3; Pax7; Cadherin; Expression regulation; Spinal 
cord. 
 
34. Applications of Virus Expression Vectors for Infectious Disease Research. 
Kathleen L. Hefferon, University of Toronto, Canada.  
Summary: As basic knowledge of the molecular biology of viruses improves, virus 
expression vectors increase in sophistication and their application in the field of medicine 
broadens. Virus expression vectors have been used as research tools for generating 
vaccines and have functioned as delivery vehicles for siRNAs, antiviral agents, and other 
drug candidates. Besides vectors based on animal viruses such as vaccinia virus, VSV, 
adeno-associated virus, lentivirus and herpesvirus, plant viruses have also been developed 
and examples of their applications are provided. The following presentation describes 
recent innovations with respect to the use of virus expression vectors for both 
therapeutics and drug development. 
 
35. Molecular adaptations of mammalian hibernation; regulation of energy 
dependent cellular processes during metabolic depression.  
Kenneth B. Storey and Michael Wu, Biochemistry at Carleton University in Ottawa, 
Canada.     
Summary: For many small mammals, survival over the winter months is a serious 
challenge because of low environmental temperatures and limited food availability. The 
solution for many species, such as thirteen-lined ground squirrels (Ictidomys 
tridecemlineatus), is hibernation, an altered physiological state characterized by seasonal 
heterothermy and entry into long periods of torpor that are interspersed with short 
arousals back to euthermia. At the cellular level, biochemical adaptations take place to 
achieve metabolic re-programming during hibernation; metabolic rate is strongly reduced 
to achieve major energy savings, via coordinated depression of non-essential ATP-
expensive functions such as protein synthesis and gene transcription. In this talk, 
molecular mechanisms that regulate metabolic depression will be discussed, including the 
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role of post-translational and transcriptional regulations in energy dependent cellular 
processes such as mTOR signaling and FoxO transcriptional response. 
 
36. Profiling the Pharmacology of GPCR Complexes.  
Kevin Pfleger, Molecular Endocrinology-GPCRs, Western Australian Institute for 
Medical Research, Australia.  
Summary: G protein-coupled receptors (GPCRs) function as multi-protein complexes, 
signalling through and being regulated by a host of other proteins including G proteins, 
arrestins, ubiquitin and other GPCRs. Our work has focused upon assessing the molecular 
pharmacology of GPCR complexes, primarily in live cells and in real-time. We have 
largely used bioluminescence resonance energy transfer (BRET) to do this, measuring the 
non-radiative energy transfer between a luciferase donor genetically fused to one protein 
of interest, and a fluorophore fused to another, following addition of a suitable luciferase 
substrate. The very high distance dependence of this energy transfer means that the donor 
and acceptor, and therefore the proteins of interest, are in very close proximity, indicative 
of complex formation. Furthermore, the real-time nature of the measurement enables 
informative kinetic profiles to be established in live cells and at physiological 
temperature. 
 
37. Cardiomyocyte Differentiation in Human Skeletal Muscle Stem Cells by 
Biophysical Factors and Post-Transcriptional Regulation.  
Jason Tchao1, M.S., and Kimimasa Tobita1,2,3, M.D., Department of Bioengineering1, 
Developmental Biology2, McGowan Institute for Regenerative Medicine3, University of 
Pittsburgh, USA.  
Summary: Heart failure results in significant cardiomyocyte (CM) loss, and post-natal 
mammalian heart has limited regenerative capacity. Cellular cardiomyoplasty has 
emerged as a novel therapy to restore contractile function of injured myocardium. 
Skeletal myoblasts can be safely isolated and showed some benefits in clinical trials, but 
high incidence of arrhythmias due to lack of electric coupling with host cells limits their 
use for cardiac repair. This limitation could be overcome by differentiating cells into 
CMs. Muscle derived stem cells (MDSC) possess greater phenotypic plasticity than 
skeletal myoblasts. Our studies showed that cardiac and skeletal muscle share major 
muscle transcription factor genes/proteins in native developing muscle and stem cell-
derived muscle cells. Therefore, it may be possible for human MDSCs to differentiate 
into CM-like cells under the appropriate conditions. The results of our studies showed 
that differentiating muscle cells from human MDSC aggregates in 3-dimensional 
engineered muscle tissue (3D-EMT) beat spontaneously, displayed cyclic calcium 
transients, expressed cardiacspecific transcription factor and structural proteins, and 
responded to cardiotropic compounds. They also possessed characteristics of skeletal 
muscle including expression of MyoD and myogenin. Their electrical coupling also 
remained immature. By temporally treating 3D-EMT with 4 chemical factors (4CF: miR-
206 inhibitor, IWR-1, BMP4, and LiCl) and improving aggregation conditions, 4CF-
EMT showed better muscle tissue formation and more cardiac-like morphology with 
improved contractility, pharmacological responses, and electrical coupling. The results 
highlight the importance of temporal control of both biophysical and posttranscriptional 
factors for CM differentiation from MDSCs. 
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38. lncRNA 7SL represses p53 translation by competing with HuR.  
Kotb Abdelmohsen, Laboratory of Cellular and Molecular Biology, NIA-IRP, NIH, 
Baltimore, MD, USA.  
Summary: Long noncoding RNAs (lncRNAs) and RNA-binding proteins (RBPs) are 
potent post-transcriptional regulators of gene expression. The lncRNA 7SL is upregulated 
in cancer cells, but its impact on the response of cancer cells is unknown. Here, we 
present evidence that 7SL forms a partial hybrid with the 3’-untranslated region (UTR) of 
TP53 mRNA, which encodes the tumor suppressor p53. The interaction of 7SL with 
TP53 mRNA reduced p53 translation, as determined by analyzing p53 expression levels, 
nascent p53 translation, and TP53 mRNA association with polysomes. Silencing 7SL led 
to increased binding of HuR to TP53 mRNA, an association that led to the promotion of 
p53 translation and increased p53 abundance. We propose that the competition between 
7SL and HuR for binding to TP53 3’UTR determines the magnitude of p53 translation, in 
turn affecting p53 levels, and the growth-suppressive function of p53. 
 
39. Regulation of osteoclast differentiation by Cx37.   
Lilian I. Plotkin, Department of Anatomy and Cell Biology, Indiana University School of 
Medicine, USA.  
Summary: Connexin (Cx) proteins are essential for cell differentiation, function and 
survival in all tissues with Cx43 being the most studied in bone. We found that Cx37, 
another member of the connexin family of proteins, is expressed in osteoclasts, 
osteoblasts and osteocytes. Mice with global deletion of Cx37 (Cx37-/-) exhibit higher 
bone mineral density, increased cancellous bone volume, and improved mechanical 
strength compared to wild type littermates. Treatment of non-adherent Cx37-/- bone 
marrow cells, which contain osteoclast precursors, with the pro-osteoclastogenic 
cytokines Receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage 
colony stimulating factor (M-CSF) rendered a 5-fold lower level of osteoclast 
differentiation compared to Cx37+/+ cell cultures. Further, Cx37-/- osteoclasts are 
smaller and have fewer nuclei per cell. mRNA expression of the RANKL receptor 
RANK, and TRAP, cathepsin K, calcitonin receptor, MMP9, NFATc1, DCSTAMP, 
ATP6v0d1 and CD44, markers of osteoclast number, fusion and activity, is lower in 
Cx37-/- osteoclasts compared to controls. In addition, non-adherent bone marrow cells 
from Cx37-/- mice exhibit higher levels of markers for osteoclast precursors, suggesting 
altered osteoclast differentiation. Osteoclast number and surface are significantly lower in 
bone of Cx37-/- mice. In contrast, mineralization of differentiating bone marrow cultures 
ex vivo, as well as circulating levels of osteocalcin and alkaline phosphatase, expression 
of osteoblast markers in bone, osteoblast number and surface and bone formation rate in 
bones from Cx37-/- mice are unchanged. Thus, Cx37 is required for osteoclast 
differentiation and fusion and its absence leads to arrested osteoclast maturation and high 
bone mass in mice. These findings demonstrate a previously unrecognized role of Cx37 
in bone homeostasis that is not compensated for by Cx43 in vivo. 
 
40. Targeting and Tackling the Cancer Stem Cell Niche.   
Lynne-Marie Postovit, Robarts Research Institute, The Schulich School of Medicine, 
Western University, USA.  
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Summary: Tumours contain populations of cells with stem cell like properties, and it is 
believed that these phenotypically plastic cells are responsible for cancer progression and 
metastatic potential.  Stem cell-like populations are regulated by dynamic niches, 
characterized by specific growth factors and extracellular matrices, as well as biophysical 
features such low oxygen tensions.  Moreover, a growing body of evidence suggests that 
cancer cells co-opt stem cell-associated regulatory networks in order to sustain plasticity.  
We have discovered that an embryonic-associated protein called Nodal maintains stem 
cell phenotypes in cancer, and that it promotes classical hallmarks of cancer such as 
angiogenesis, invasion and metastasis.  We have also found that biophysical features of a 
growing tumour, in particular hypoxia, can promote tumour cell plasticity by up-
regulating embryonic proteins like Nodal via a combinatorial mechanism. Finally, we 
have determined that exposure to normal embryonic stem cell factors can reprogram 
metastatic cancer cells toward a more differentiated, less tumourigenic phenotype.  We 
are currently using quantitative SILAC-based proteomics together with developmental 
and cancer model systems to identify potential anti-tumourigenic proteins in stem cell-
derived extracellular matrices; and to further understand how cancer cells hijack 
developmental signalling cascades to facilitate progression.  By studying the mechanisms 
by which cancer cells acquire and sustain phenotypic plasticity, we may uncover novel 
targets for the prediction and prevention of tumour progression.  
 
41. The pro-apoptotic protein, Bax, forms highly cooperative, voltage-gated 
channels. 
Marco Colombini, Dept. Biology, University of Maryland, USA. 
Summary: Pending. 
 
42. Ox-LDL and Inflammatory Environment Shift Angiogenic Endothelial 
Progenitor Cells into Functional Antigen Presenting Cells.  
Maria Cristina Vinci, Cardiovascular Tissue Engineering Laboratory, Centro 
Cardiologico Monzino, IRCCS, Italy.  
Summary: At present, two endothelial progenies, early and late endothelial progenitor 
cells (EPCs), were identified according to their in vitro onset, lineage, and functional 
properties. Both cell types synergistically provide instructive (release of angiogenic 
cytokines) and structural (vessel incorporation and stabilization) functions that promote 
the initiation of neo-angiogenesis. Early-EPCs (eEPCs), also referred as myeloid 
angiogenic cells, are an important EPC subtype obtained in vitro from mononuclear cell 
fraction after one week of culture in angiogenic medium. The paracrine pro-angiogenic 
function of these cells has been well established. Several preclinical studies have indeed 
demonstrated their active participation in EC regeneration/vasculogenesis either as 
cellular placeholders of the injured endothelium, or as cytokine ‘factories’ for 
ECvascular-regenerating cells. Early EPC precursors (monocyte/macrophage 
mononuclear cell population) are characterized by a hidden plasticity which allows them 
to behave as multi/pluripotent stem cell under appropriate micro-environmental 
conditions. Nevertheless, angiogenic eEPCs have been extensively proposed in 
regenerative medicine regardless of their trans-differentiation potential and response to 
the host’s micro-environment. In the present study we demonstrated that high levels of 
pro-inflammatory cytokines and oxidized-LDL, commonly present in advanced 
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atherosclerotic plaque milieu, shifted EPC commitment into functional 
inflammatory/immunomodulatory antigen presenting cells (APCs) with a distinct 
paracrine and transcriptional profile and potentially harmful cardiovascular effects. 
 
43. Novel uses of circular variance for macromolecular analyses.  
Mihaly Mezei, Department of Structural and Chemical Biology, Mount Sinai School of 
Medicine, USA.  
Summary: The concept of circular variance has been shown to be useful for the 
characterization of macromolecular topography. The talk will discuss the use of circular 
variance for the characterization of molecular surface ruggedness and the possibility of 
using it for predicting protein-protein interaction interfaces. In addition, the idea of a 
putative Achilles’ heel of a protein, which resulted from work with circular variance, will 
be discussed.  
 
44. Prostate cancer stem cell, midkine protein and lithium chloride.  
Mine Ergüven, 2 Gülperi Öktem, 3 Ali Nail Kara,  4 Ayhan Bilir 1 İstanbul Aydın 
University, Faculty of Engineering, İstanbul, Turkey; 2 Department of Histology And 
Embryology, Ege University, Faculty of Medicine, İzmir, Turkey; 3 2nd Term Student, 
İstanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey; 4 Department of 
Histology and Embryology, İstanbul University, İstanbul Faculty of Medicine, İstanbul, 
Turkey.  
Summary: The aim of this study was to investigate the effects of lithium chloride (LiCl) 
which has been established for more than 60 years as effective bipolar disorder treatment 
and is lately pronounced with its’ antineoplastic effects on prostate stem cells through 
survival protein midkine (MK) levels. Human prostate cell line DU145 (HTB-81) was 
provided from American Type Culture Collection and cultured in monolayer. Cells were 
sorted by using FACS Diva flow cytometry (BD Biosciences) and cancer stem cell group 
was labeled as (+). Cells were incubated with low concentrations (1 μM, 10 μM) and high 
concentrations (100 μM, 500 μM) of LiCl for 72 hours. Total cell numbers, apoptotic 
index (flow cytometric Annexin-V-FITC/PI staining) and MK levels (ELISA) were 
evaluated. Istatistical analysis was proceeded with SPSS 17.0 program by using Student-
t-Test. P<0.05 value was considered statistically significant. LiCl showed concentration 
and time dependent effect at both DU 145 (+) and DU 145 (-) groups (p<0.05). In 
comparison to control group and high LiCl concentrations, low LiCl concentrations 
increased cell numbers with MK levels and decreased apoptotic index (p<0.05) in all 
groups . It’s determined that DU 145 (+) group was more resistant to the inhibitory action 
of LiCl, responded faster to its’ stimulative action, and possessed higher MK levels 
(p<0.05.) In this study, it’s shown for the first time that the effects of LiCl on prostate 
cancer stem cells is biphasic and MK levels were shown to change in direct proportion to 
that effect. Keywords Prostate cancer, Lithium chloride, Cancer stem cell, Midkine. 
 
45. Decellularized stem cell matrix mediated cartilage regeneration and its 
significance for regenerative medicine.  
Ming Pei, Stem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, 
West Virginia University, Morgantown, WV 26506-9196, USA.  
Summary: Cell-based therapy is a promising biological approach for the treatment of 
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cartilage defects. Due to the small size of autologous cartilage samples available for cell 
transplantation in patients, chondrocytes need to be expanded to yield sufficient cell 
number for cartilage repair. However, either chondrocytes or adult stem cells tend to 
become replicatively senescent once they are expanded on conventional plastic flasks. 
Many studies demonstrate that the loss of cell properties is concomitant with the 
decreased cell proliferation capacity. This is a significant challenge for cartilage tissue 
engineering and regeneration. Despite much progress having been made in cell 
expansion, there are still concerns over expanded cell size and quality for cell 
transplantation application. Recently, in vivo investigations in stem cell niches have 
suggested the importance of developing an in vitro stem cell microenvironment for cell 
expansion and tissue-specific differentiation. Our and other investigators’ work indicates 
that a decellularized stem cell matrix (DSCM) may provide such an expansion system to 
yield large-quantity and high-quality cells for cartilage tissue engineering and 
regeneration. Further investigations of the underlying mechanism and in vivo 
regeneration capacity will allow this approach to be used in clinics in the near future. In 
this talk, tissue-specific stem cell will also be highlighted for a lineage-specific tissue 
regeneration, which guarantees an engineered cartilage tissue with high quality. This new 
strategy is also applied to other lineage tissue regeneration. 
 
46. Metabolomics, Metaboloepigenomics, Polyomics.  
Miroslava Cuperlovic-Culf, National Research Council of Canada, Moncton, Canada.  
Summary: Analysis of metabolites has been part of research in life sciences for 
centuries. Metabolomics, defined as the high throughput study of metabolites, has a solid 
base in early metabolic studies as well as development of analytical and computational 
tools. Metabolomics holds the greatest potential in the analysis of biological systems for 
variety of reasons. Metabolic profiling can be performed on tissues, cells, body fluids and 
breath both in vivo and ex vivo. Metabolomics can be combined with other type of omics 
as well as biological and clinical data. Metabolism is also closely related to epigenetic 
changes of cells; hence metabolic profiling can be used for the investigation of 
epigenetics of cells while metabolites can influence epigenics of cells. Within our group 
we have been involved in many of these different types of analysis. In this talk I will 
provide an overview of some of our results touching on the variety of metabolomics 
applications including tumour subtyping, analysis of various drug effects of cells, 
investigation of histone deacetylase relationship with metabolism in human tumours as 
well as other organisms. Although biological results and applications will be the primary 
focus of this talk, number of different data analysis methodologies will also be outlined. 
 
47. Diagnostic yield of primary circulating tumor cells in women with suspicion of 
breast cancer: Study BEST (Breast Early Screening Test).  
Nigel P Murray, Roxana Miranda, Amparo Ruiz, Elsa Droguett. Hospital de Carabineros 
de Chile, Santiago, Chile.  
Summary: Objective: To determine the diagnostic yield of primary circulating tumor 
cells in women with suspicion of breast cancer, detected as a result of an abnormal 
mammography. Methods and Patients: Consecutive women presenting for breast biopsy 
as a result of a mammogram BiRADs 3 o more, had an 8ml blood sample taken for 
primary circulating tumor cell (CTC) detection. Mononuclear cells were obtained using 
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differential gel centrifugation and CTCs identified using standard immunocytochemistry 
using a cocktail of anti-pancytokeratin and anti-mammoglobin. A test was determined to 
be positive if 1 CTC was detected. Positive biopsy and CTC samples underwent 
immunophenotype for estrogen and progesterone receptors, HER-2 and metalloproteinase 
2 expression. Results: 144 women with a mean age of 54.7 ± 15.6 years participated, 
78/144 (53.0%) had breast cancer on biopsy, 65/140 (46.3%) benign pathologies y 
1(0.7%) Non-Hogkins Lymphoma. Increasing BiRADs score was associated with 
increased cancer detection (p=0.004, RR 1.00, 4.24, 8.50). CTCs cytokeratin positive and 
mammoglobin positive had a sensitivity of 89.55% and 81.1% and specificity of 84.4% 
and 90.9% respectively. For cytokeratin and mammoglobin positive CTCs the PPVs were 
87.2% and 90.9% and NPVs 87.1% and 81.1% respectively.  Neither marker was positive 
for the 6 intraductal carcinomas, for infiltrative cancer, cytokeratin detected 98% of 
cancers and mammoglobin 87%, poorly differentiated cancers were mammoglobin CTC 
negative. Both markers were negative in 6 of 12 (50%) of cancer in situ. Expression of 
estrogen and progresterone receptors in CTCs was concordant with the primary tumor, 
whereas HER-2 and MMP-2 expressions were significantly higher in primary CTCs. 
There was a significant trend (p<0.0001 Chi squared for trends) in CTC detection 
frequency from intraductal, in situ and invasive (OR 1.00, 8.00, 472.00). Conclusions: 
The use of primary CTC detection in women with suspicion of breast cancer has potential 
uses, especially with invasive cancer, however failed to detect intra-ductal cancer and in 
50% of in situ cancer. Further larger scale studies are warranted, to try to reduce the 
number of unnecessary biopsies, especially in women with BIRADs 4 mamagrams. The 
different phenotypic expression of CTCs for HER-2 and MMP-2 may have implications 
for targeted therapy. Key words: breast cancer detection, circulating tumor cells, 
mammogram, HER-2. 
 
48. Functions of p63 and its miR-205 target in cell migration and metastasis.   
Paola Tucci, Department of Pharmacy, Health and Nutritional Sciences, University of 
Calabria, Italy.  
Summary: The precise role of p63 in tumour progression and metastasis has been hotly 
debated and the molecular mechanisms that underlie the role of p63 in tumour are not 
clearly described. Although some studies show p63 overexpression in human cancer, 
some demonstrate a loss of p63 associated with tumour progression and metastasis. Much 
of this controversy is due to the existence of multiple isoforms. The full-length TA 
isoform of p63 bears structural and functional similarity to p53, whereas the ΔN isoforms 
of p63, which lack the transactivation (TA) domain, act primarily in dominant-negative 
fashion against p53, TAp63 and TAp73. The clinical problem of human cancer is 
metastasis. There is now evidence that, perhaps as a reflection of its role in epithelial 
development and in stemness, p63 as an “epithelial organizer” is also important in 
epithelial to mesenchimal transition (EMT), an essential prerequisite for invasion and 
migration of tumour cells.  Transcription factors exert their effects not only by regulating 
transcription of protein coding sequences, but also by activating or repressing expression 
of small non-coding RNA sequences such as micro-RNAs (miRs). In this study we show 
that p63 (both TAp63 and ΔNp63 isoforms) regulates expression of miR-205 in prostate 
cancer cells, and miR-205 is essential for the inhibitory effects of p63 on markers of 
EMT, such as ZEB1 and vimentin.  Correspondingly, the inhibitory effect of p63 on 
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EMT markers and cell migration is reverted by anti-miR-205. p53 mutants inhibit 
expression of both p63 and miR-205, and the cell migration, in a cell line expressing 
endogenous mutated p53, can be abrogated by pre-miR-205 or silencing of mutated p53. 
In accordance with this in vitro data, ΔNp63 or miR-205 significantly inhibits the 
incidence of lung metastasis in vivo in a mouse tail vein model. Similarly, one or both 
components of the p63/miR-205 axis were absent in metastases or colonized lymph nodes 
in a set of 218 human prostate cancer samples. This was confirmed in an independent 
clinical data set of 281 patients. Loss of this axis was associated with higher Gleason 
scores, an increased likelihood of metastatic and infiltration events and worse prognosis. 
These data suggest that p63/miR-205 may be a useful clinical predictor of metastatic 
behaviour in prostate cancer. 
 
49. Circulating complementary innate IgM originating from ancestral antigen 
completeness in reduction of O-glycosylations.    
Peter Arend, ret. Philipps University of Marburg/Lahn, Germany.  
Summary: The murine and human immune systems have fundamental properties in 
common.  E.g. the histo (blood) group anti-A-specific complementary IgM in the mouse 
and related human innate isoagglutinin represent developmen-tal, 2-mercaptoethanol-
sensitive, complement-binding glycoproteins, which do not arise from any measurable 
environmentally-induced or auto- immune response. So the murine glycoprotein 
appearing in parallel with auto-reactive O-glycan-bearing ovarian glycolipids certainly 
originates from a cell surface- or cell adhesion molecule, which in the course of germ cell 
development becomes devoid of O-GalNAc-transferase activity and is released into the 
circulation. In human sera a blood group AB-reactive α2-macroglobulin occurs together 
with O-GalNAc-transferase activity exclusively in those of blood group A- and AB 
subjects, while in group O(H) an identically encoded protein, but devoid of the 
transferase activity, suggests an opposite function and appears in conjunction with a 
complementary anti-A reactive IgM-like glycoprotein. Since O-glycosylations rule the 
carbohydrate metabolism in growth and reproduction processes, we have proposed that 
the ancestral histo-(blood)-group A-molecule arises in the course of O-GalNAc-
glycosylations of glycolipids and protein envelops at progenitor cell surfaces. Germ cell 
development postulates embryonic stem cell fidelity, which is characterised by persistent 
production of α-linked O-GalNAc-glycans, encoded by the A-allele of a “complete” histo 
(blood) group AB (O) structure that in early ontogeny is hypothesised to be synthesised 
independently from the final phenotype. The structure either passes “completely” through 
the germline, in mature tissues becoming the “complete” phenotype AB, or disappears in 
exhaustive glycotransferase depletion from differentiating cell surfaces and leaves behind 
the “incomplete” blood group O-phenotype, which has released a transferase- and O-
glycan-depleted, complementary glycoprotein (IgM) into the circulation. The process 
implies, that in humans the different blood phenotypes evolve from a “complete” AB (O) 
molecular complex in a dis-tinct enzymatic and/or complement cascade suggesting O-
glycanase activities. While the murine and human oocyte zona pellucida express identical 
O-glycans, the human phenotype O might be explainable by the kinetics of the murine 
ovarian O-GalNAc-glycan synthesis and the complementary anti-A released into the 
circulation. So the maturing murine ovary may provide insight into encoding of the 
physiologically superior α-linked O-GalNAc ancestral epitope that becomes essential in 
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reproduction as well as in tissue renewal events. And human stem cell generation based 
on oocyte genome transitions may capitalise on an obviously pronounced fertility of by 
O-glycosylation- protected reproduction in blood group A females. Abbreviations: IgM: 
Immunoglobulin M; O-GalNAc: O-N-acetyl-D-galactosamine. 
 
50. Application of human cardiomyocytes derived from pluripotent stem cells for 
toxicity testing and disease modeling.  
Peter Sartipy, Stem Cell Discovery and Senior Principal Scientist, Cellectis AB, Arvid 
Wallgrens Backe 20, 413 46 Göteborg, Sweden.   
Summary: Human pluripotent stem cells can be differentiated with high efficiency to 
cardiomyocytes in 2D and 3D cultures. Extensive characterization of the differentiated 
cardiomyocytes has shown that the cells share many similarities with bona fide human 
cardiomyocytes, while some functional aspects remain fetal-like. Even though much 
research remains to generate fully mature cardiomyocytes, the current state-of-the-art 
processes of cost-effective derivation of cardiomyocytes from hPSCs have been 
standardized and implemented in industrial settings. The cells are now being used for in 
vitro applications in drug discovery. The utility of these cells in long term toxicity testing 
and repeated dose toxicity testing will be demonstrated as well as bench-marking studies 
comparing in vitro testing with animal experimentation. In addition, induced pluripotent 
stem cells created from healthy donors and individuals suffering from specific diseases 
now allow detailed investigations of drug responses and potential adverse effects in 
physiologically relevant model systems.  
 
51. Presentation Title: Pending.  
Rahul Saxons, Department of Biochemistry and Molecular & Cellular Biology 
Georgetown University Medical Center, Washington, USA.  
Summary: Pending. 
 
52. FKBP51 orchestrates the evil axis EMT/ cancer stemness/drug resistance, in 
malignant melanoma: a matter of protein/protein interaction . 
Romano Maria Fiammetta, Department of Biochemistry and Medical Biotechnology, 
Federico II University of Naples, Naples, Italy.  
Summary: Recent breakthroughs suggest that induction of the EMT transdifferentiation 
program in cancer cells enables them not only to disseminate from primary tumours and 
form metastases, but also to acquire resistance to therapy and self-renewal capability 
which is crucial to their subsequent expansion at sites of dissemination. In recent years, 
research studies from our laboratory highlighted functions for the FK506 binding protein 
51 (FKBP51) in the control of apoptosis, invasiveness and aggressiveness of melanoma. 
Herein, we show that FKBP51 acts as a cochaperone of IKK components and the general 
transcriptional coactivator p300 and, the interactions between a deregulated FKBP51 and 
these proteins enable melanoma to resist apoptosis and promote CSC and EMT genetic 
programs. Our findings point to FKBP51 as a common denominator to EMT, cancer 
stemness and drug resistance, in melanoma. 
 
53. Is it possible to fight influenza by targeting intracellular redox state?  
Rossella Sgarbanti, Università Telematica San Raffaele, IRCCS San Raffaele Roma, 
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Italy.  
Summary: Influenza viruses induce a redox imbalance in the host cells, characterized by 
depletion of the main intracellular antioxidant glutathione (GSH) and increase in 
Reactive Oxygen Species (ROS). This oxidative stress may play a role in activating 
intracellular redox-sensitive pathways that are exploited by the virus for its own 
replication. The activation of the redox-regulated machinery may also play a role in the 
dysregulated pro-inflammatory responses and severe lung injury caused by highly 
pathogenic influenza viruses. We have recently demonstrated that it is possible to inhibit 
influenza virus replication by treating infected cells or mice with a derivative of GSH, 
GSH-C4. In particular, GSH-C4 is able to impair hemagglutinin (HA) maturation in the 
endoplasmic reticulum and, as a consequence, to block the progression of virus 
replicative cycle. This effect is related to the correction of virus-induced GSH depletion 
that, in turn, affects the redox state of PDI, a cellular oxidoreductase involved in disulfide 
bond formation of glycoproteins. It has also been demonstrated that pro-GSH molecules, 
including GSH-C4, are able to increase the intra-macrophage thiol content in vitro and in 
vivo as well as to shift the immune response towards Th1 which plays a pivotal role in 
antiviral immunity. Our aim was to investigate whether: i) the ability to induce oxidative 
stress in the host cell depends on the type of viral strain (human or avian viruses); ii) 
eradication of oxidative stress inflicted by influenza virus, by using different redox 
modulator compounds, would affect infectivity and/or to prevent excessive cytokine 
production. We found that human influenza virus induced a continuous and progressive 
increase of intracellular ROS levels from three to five hours after infection. Avian virus 
induced multiple waves of ROS hyperproduction and the ROS levels were significantly 
higher than that observed in cells infected with human virus. Among different redox 
modulating compounds tested, differently from GSH-C4, N-acetyl cysteine (a GSH 
precursor) and Trolox (a derivative of Vitamin E with ROS scavenging activity) 
exhibited short-term anti-influenza activity in infected lung epithelial cells, without 
interfering with viral protein expression or HA folding. In addition, these compounds 
produced different effects on the inflammatory cytokine production, suggesting that 
different redox-regulated pathways (GSH-mediated or ROS-mediated) may be 
specifically involved in the regulation of virus life-cycle and/or inflammatory responses. 
Overall, these results indicate that GSH-C4 is effective in both inhibiting influenza virus 
replication and blocking the cytokine storm responsible for the lethality of some viral 
strains. Our data also demonstrate that not all the so-called “antioxidant drugs” are able to 
control viral infection and inflammatory responses. Thus, the efficacy of a specific 
compound depends on its real ability to affect redox-regulated pathways in different 
cellular contexts. 
 
54. Sexually dimorphic microRNA expression: a new thought on sex bias of 
autoimmune diseases.  
Rujuan Dai, Department of Biomedical Sciences and Pathology, Virginia-Maryland 
Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA24060, USA.  
Summary: A striking feature of autoimmune diseases is that a majority of these 
disorders occur predominantly in females: about 80% of autoimmune patients are 
women. The basis of sex bias in autoimmune diseases is complex and remains elusive. It 
potentially involves multiple factors such as sex chromosomes, sex hormones, sex-
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specific gene expression regulation and environmental exposures. Systemic Lupus 
Erythematosus (SLE) is a prototype, female predominant autoimmune disease. 
microRNAs (miRNAs) are small, non-coding RNAs that are critically involved in the 
pathogenesis of a broad range of human diseases including autoimmune lupus. We have 
recently reported a common set of lupus-associated miRNAs including miR-182-96-183 
cluster, miR-155, miR-31, miR-127, and miR-379 in three spontaneous murine lupus 
models including NZB/WF1, a classical murine lupus model with significant female bias. 
We further hypothesized that miRNAs are differentially expressed between males and 
females in the context of autoimmune diseases, leading to sex differences in disease 
susceptibility and severity. To test this hypothesis, we analyzed aforementioned lupus-
associated miRNAs expression in splenocytes from male and female NZB/WF1. We 
found that the sex differences in the expression of lupus-associated miRNAs in 
splenocytes were markedly evident after the onset of lupus. Prior to the onset of lupus, 
only miR-127 and miR-379 displayed slight, but significant increase in female NZB/WF1 
mice when compared to age-matched male counterparts. Considering that female 
hormone estrogen plays an important role in the sex differences in immune function and 
autoimmunity, we investigated the effect of estrogen on miRNA expression in the context 
of lupus.  Our data indicated that estrogen treatment of orchidectomized male NZB/WF1 
mice promoted the expression of lupus-associated miRNAs including miR-182-96-183 
cluster, miR-379, and miR-148a, but did not affect miR-155 in splenocytes. Together, our 
study demonstrated that female NZB/WF1 mice displayed increased expression levels of 
lupus-associated miRNAs after the onset of lupus when compared to age-matched males.  
Importantly, these miRNAs were disease associated and were upregulated by estrogen 
treatment. We believe that the finding of sexually differential expression and estrogen 
regulation of miRNA in the context of lupus shall provide us new perspective to 
understand the mechanism of sex bias of autoimmune lupus.  
 
55. Expressioneering Technology accelerates Functional Expression and 
Crystallization of GPCRs for Drug Discovery.  
Saurabh Sen, R&D, Lucigen Corp, USA.  
Summary: Structural biology of membrane proteins and GPCRs has seen major 
advances over the past few years, but overcoming the challenges of functional GPCR 
expression and structural stabilization are still time-consuming and expensive. We are 
developing new tools to streamline these processes, and further enhance the pace of drug 
discovery. We present the application of several new technologies to the challenges of 
functional membrane protein expression. A rapid recombination-based cloning 
technology accelerates optimal GPCR expression through fusion to a variety of 
transmembrane guides and novel visualization tags. We have been successful in rapidly 
generating and expressing hundreds of brain GPCR fusion constructs in E. coli and 
mammalian cells with this system. We will also present our use of a novel fluorescent 
protein, LucY (for Lucigen Yellow) in a loop insertion strategy to express stabilized 
GPCRs for crystallization trials. This strategy allows fluorescent visualization of 
membrane proteins during expression, solubilization, purification, and crystallization. We 
have found that insertion of LucY into ICL3 of GPCRs allows retention of ligand-binding 
activity and may promote GPCR crystallization. We have obtained fluorescent putative 
crystals of turkey β1-adrenergic receptor expressed in bacterial cells using a rhamnose 
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promoter system with LucY inserted in the ICL3. We are also applying this strategy to 
human brain GPCRs.  
 
56. Vesicular trafficking protein, Rab25 is a conditional oncogene in breast cancer. 
Shreya Mitra, Department of Systems Biology, University of Texas MD Anderson Cancer 
Center, USA.  
Summary: Pending. 
 
57. MicroRNAs in the malignant transformation of colon adenoma to 
Adenocarcinoma. 
Subbaya Subramanian, Department of Surgery, The University of Minnesota, USA.  
Summary: Progression from benign adenoma to colon cancer is a complex multi-step 
process mediated by genetic alterations in driver genes. Although miRNAs are implicated 
in this multihit model of progression, their precise role during the transformation of colon 
adenomas to adenocarcinoma is unknown. This talk will discuss the role of miRNAs in 
the transformation of colon adenoma to adenocarcinoma by cooperatively regulating the 
tumor suppressor driver gene, FBXW7. Our studies show that a step-wise expression of 
miRNAs in benign adenoma synergistically regulates the driver genes such as FBXW7, 
thus contributing to the progression of colon adenoma to adenocarcinoma.  
 
58. Monte Carlo simulation elucidates the type 1/ type 2 choice in apoptosis under 
death ligand induction.  
Subhadip Raychaudhuri, Indraprastha Institute of Information Technology, India.  
Summary: The problem of understanding type 1/type 2 choice in apoptosis is crucial for 
exploring the systems level regulatory mechanisms of cell death activation and is of 
much current interest. To address this important biological problem we have carried out 
in silico studies of apoptosis signaling under death ligand induction. A hybrid Monte 
Carlo simulation has been developed that can link a free energy based model of 
membrane proximal events with the type 1/type 2 pathways of signaling. Our results 
indicate that the type 1/type 2 choice is regulated at a system level and cell-type specific 
expression levels of signaling molecules shape the phase diagram. Effects of some of the 
key molecules, such as those involved in opening and closing of the type1/type 2 loop, 
are analyzed in the context of experimental observations. In addition, death ligand 
concentration is shown to have a key role in deciding between the type 1 and type 2 
pathways as increased level of death ligands resulted in increased type 1 activation, 
irrespective of cell types. We also explored the type 1/type 2 choice in cancer cells 
having markedly altered proteome (compared with healthy cells) and its implications for 
selective killing of cancer cells. Our results indicate that inherent differences in the 
membrane proximal signaling module, between cancer and healthy cells, can allow such 
selective activation of apoptosis in tumor cells.  
 
59. Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 
nuclease-induced mutations. 
Suresh Ramakrishna, Stem Cell Research, College of Medicine, Hanyang University, 
Seoul-133-791, South Korea.  
Summary: RNA-guided endonucleases (RGENs), which are based on the clustered, 
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regularly interspaced, short palindromic repeat (CRISPR)-CRISPR-associated (Cas) 
system, have recently emerged as a simple and efficient tool for genome editing. 
However, the activities of prepared RGENs are sometimes low, hampering the generation 
of cells containing RGEN-induced mutations. Here we report efficient methods to enrich 
cells containing RGEN-induced mutations by using surrogate reporters. HEK293T cells 
are cotransfected with the reporter plasmid, a plasmid encoding Cas9, and a plasmid 
encoding crRNA and tracrRNA, and subjected to flow cytometric sorting, magnetic 
separation, or hygromycin selection. The selected cell populations are highly enriched 
with cells containing RGEN-induced mutations, by a factor of up to 11-fold as compared 
with the unselected population. The fold enrichment tends to be high when RGEN 
activity is low. We envision that these reporters will facilitate the use of RGEN in a wide 
range of biomedical research. 
 
60. Presentation Title: Pending.  
Tammy A. Butterick-Peterson, Minnesota Obesity Neuroscience Lab  Group, University 
of Minnesota, USA.  
Summary: Pending. 
 
61. Deficient Aldehyde Dehydrogenase 1A1 Expression In Primary Cells Isolated 
From Gorlin Syndrome Patients:  Implications For Radiation Carcinogenesis and 
Developmental Defects.    
Thomas Weber, FSD/Cell Biology and Biochemistry, Pacific Northwest National 
Laboratory, USA.  
Summary: Many cancer prone human phenotypes have been identified.  Sensitive 
phenotypes often display robust regulation of molecular features that modify biological 
response, which can facilitate identification of the pathways/networks that contribute to 
pathophysiological outcomes.  We have interrogated primary dermal fibroblasts isolated 
from Gorlin Syndrome patients (GDFs), who display a pronounced inducible tumorigenic 
response to radiation, in comparison to normal human dermal fibroblasts (NHDFs) using 
newly developed thiol-reactive probes to define changes in protein thiol profiles in live 
cell studies.  Redox probes revealed deficient expression of aldehyde dehydrogenase 1A1 
(ALDH1A1), a key enzyme regulating retinoic acid synthesis, and ALDH1A1 protein 
deficiency in GDFs was confirmed by Western blot.   A number of additional protein 
thiol differences in GDFs were identified, including radiation responsive annexin family 
members.  The molecular features identified in our study are of likely importance to 
cancer susceptibility in Gorlin Syndrome patients and radiation health effects broadly.  
 
62. Alcohol: A Glimpse at Direct, and Indirect Organ Damage; With Application to 
Future Research.  
Tiana V. Curry-McCoy, Medical Laboratory Imaging Radiologic Sciences-Clinical 
Laboratory Science, College of Allied Health Sciences, Georgia Regents University 
(MCG&ASU), USA.  
Summary: Alcoholism is best known to have damaging effects on the liver and brain. It 
is commonly known that alcohol can be detected in urine and blood. The transfer of 
alcohol from the “first pass” mechanism of mouth, esophagus, stomach, liver through to 
blood which distributes alcohol on its “second pass” to other bodily organs such as the 
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lungs and sex organs. Here we will discuss cellular damage from alcohol and its 
secondary metabolites to the liver and the lung. In our liver studies we hypothesized that 
the lack of cellular Cu/Zn-SOD, an enzyme that prevents cellular damage from 
superoxide, would induce increased generation of oxidants, thereby causing damage to 
hepatic proteins, and the hepatic proteolytic system. We used SOD1 null and wild type 
mice to determine how ethanol-induced oxidation and nitration altered hepatic proteins 
and how hepatic proteolytic systems are effected by ethanol-induced oxidative stress in 
vivo. Next, in alveolar cells we performed in vitro experiments exposing the rat AM cell 
line (NR8383) to 0.2% ethanol for four weeks. We also exposed these cells to 
granulocyte-macrophage colony-stimulating factor (GM-CSF) for 24 hours. Next, we 
performed in vivo studies using AM and epithelial cells from control and alcohol-fed rats. 
Gene expression and DNA binding in these cells were examined independently or after 
overnight treatment with GM-CSF. Intracellular zinc levels were measured by flow 
cytometric analysis of cells that were stained with FluoZin-3. It is our belief that 
understanding of alcohol damage to the total body will help research and treatment of this 
disease.  
 
63. Signal transduction in innate immunity - what can we learn from the Caspase 
Activation Domains (CARDs) of the NLR family members NOD1 and NOD2. 
Tom Monie, Department of Biochemistry, University of Cambridge, Cambridge, UK.  
Summary: Pending. 
 
64. The involvement of Phosphoinositide signal transduction pathway in 
angiogenesis. 
Vincenza Rita, Surname Lo Vasco, Department of Sense Organs, Sapienza University of 
Rome, Italy.  
Summary: Besides the control of calcium levels, the Phosphoinositide-specific 
phospholipases C (PI-PLCs), main players in the Phosphoinositide signalling pathway, 
contribute to a number of cell activities. The signalling system of Phosphoinositides (PIs) 
is involved in a variety of cell and tissue functions, including membrane trafficking, ion 
channel activity, cell cycle, apoptosis, differentiation, cell and tissue polarity. Recently, a 
role in cell migration was hypothesized for PI and related molecules, such as the 
phosphoinositide-specific phospholipases C (PI-PLCs), main players in PI signalling. The 
expression of PI-PLCs is tissue specific, and evidences suggest that it varies under 
different conditions, such as tumour progression or cell activation. In order to obtain a 
complete panel, we first analyzed the expression of all PI-PLC isoforms in human 
endothelial cells (EC). We investigated the human umbilical vein endothelial cells 
(HUVEC), a widely used experimental model. Then, we analyzed the mRNA 
concentration of PI-PLCs in LPS treated HUVEC by using the multiliquid bioanalyzer 
methodology after 3, 6, 24 48 and 72 hours from LPS administration. Marked differences 
in the expression of most PI-PLC codifying genes were evident, suggesting that the 
expression of the PLC genes varies under inflammatory stimulation. The Fibroblast 
Growth Factor (FGF) activates the PI- -PLCs 
expression in FGF treated HUVEC was performed by using RT-PCR, observed after 24 
hours from stimulation. The expression of selected genes after stimulation was perturbed, 
suggesting that FGF affects gene transcription in PI signalling as a possible mechanism 
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of regulation of its activity upon the AkT-PLC pathway. The most efficient effects of 
FGF were recorded in the 3-6hrs interval. The growing interest for the complex cascade 
of events occurring in angiogenesis will provide useful insights for therapeutic strategies. 
However, although HUVEC represent a widely used experimental model for human 
macrovascular EC, limitations remain in that they cannot fully represent the metabolic 
properties and interactions of the EC distributed in the entire organism. 
 
65. Bioprinted Neocartilage Formation in Poly(ethylene) Glycol and Gelatin 
Methacrylate Copolymer Using Human Mesenchymal Stem Cells.  
Xiaofeng Cui, Institute of Advanced Study, Technical University of Munich; Director of 
Research, Stemorgan Therapeutics, New York, USA.  
Summary: Current cartilage tissue engineering strategies still can yet fabricate new 
tissue that is indistinguishable from native cartilage with respect to zonal organization, 
extracellular matrix composition, and mechanical properties. Integration of implants with 
surrounding native tissues is crucial for long term stability and enhanced functionality. 
Direct cartilage repair with engineered tissue closely mimicking native cartilage to the 
site of the lesion without any additional damage to the existing healthy tissue is therefore 
very attractive. The ideal implanted tissue is expected to integrate with existing native 
cartilage and to repair lesions of different sizes and thicknesses. The multifaceted mature 
of this challenge requires a technique adaptable to variable physical dimensions and 
properties for tissue repair; we believe that bioprinting, based on inkjet printing 
technology, provides the necessary capabilities. A copolymer of poly(ethylene glycol) 
dimethacrylate and gelatin methacrylate was used to suspend human mesenchymal stem 
cells to form the bioink. The cartilage construct was printed in a layer-by-layer fashion. 
The copolymer demonstrated a great integration with the native tissue as well as excellent 
compressive modulus, which was close to the range of reported properties of native 
human articular cartilage. Printed human stem cells maintained their originally deposited 
positions due to simultaneous photopolymerization. This is ideal in precise cell 
distribution for zonal cartilage engineering. Gene expression and biochemistry analysis of 
printed neocartilage showed increased cartilage gene expression and extracellular matrix 
production in chondrogenic differentiation medium during the culture. Therefore, this 
copolymer is an ideal bioink to support mesenchymal stem cells for cartilage tissue 
engineering. 
 
66. Reciprocal regulation of microRNA and long non-coding RNAs in cancer cells. 
Yin-Yuan Mo, Cancer Institute, University of Mississippi Medical Center, Jackson, MS, 
USA.  
Summary: In addition to protein-coding genes, the human genome makes a large amount 
of non-coding RNAs including microRNAs and long non-coding RNAs (lncRNAs). Both 
microRNAs and lncRNAs have been shown to play a critical role in regulation of cellular 
processes such as cell growth and apoptosis as well as cancer progression and metastasis. 
It is well known that microRNAs can target a large number of protein-coding genes. 
However, little is known whether microRNAs can also target lncRNAs. Furthermore, it is 
largely unknown whether microRNAs can be regulated by lncRNAs. In the present talk, I 
will discuss our recent work in this front and provide three examples of microRNA-
lncRNA interactions, through which they may impact tumorigenesis. For example, miR-
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21 is a well-known oncogenic microRNA that can target a larger number of protein-
coding genes. Of interest, we showed that miR-21 is also capable of repressing the 
growth arrest specific 5 (GAS5) lncRNA which was previously shown to be involved in 
growth arrest. This negative regulation between miR-21 and GAS5 was also detected in 
breast tumor specimens. Moreover, GAS5 can also repress miR-21 expression. RNA 
precipitation assays with biotin-labeled GAS5-RNA probe was able to pull down the 
RNA-induced silencing complex (RISC) and subsequently identified miR-21 in this 
GAS5-RISC complex, implying that miR-21 and GAS5 may regulate each other in a way 
similar to the microRNA-mediated silencing of target protein-coding mRNAs. Finally, 
we demonstrated a similar regulation mechanism for RoR and miR-145, loc285194 and 
miR-211. Together, these results suggest that microRNAs can target not only tumor 
suppressive protein-coding genes, but also lncRNAs; as the same time, microRNAs are 
also under control of lncRNAs.   
 
67. Development of sexually dimorphic nuclei and the influence of estrogen-like 
compound exposure.  
Zhen He1, 2, Sherry Ann Ferguson1, Li Cui 2, Lazar John Greenfield2, Merle Gale 
Paule1 1 Division of Neurotoxicology, National Center for Toxicological Research, Food 
and Drug Administration, Jefferson, AR 72079, USA; 2 Department of Neurology, 
University of Arkansas for Medical Sciences, Little Rock, AR 72005, USA. 
Summary: One of the well-defined sexually dimorphic structures in the brain is the 
sexually dimorphic nucleus of the preoptic area (SDN-POA) in the hypothalamus. This 
presentation covers the following topics: Background information concerning the SDN-
POA. How the SDN-POA is studied. The effects of estrogens and estrogen-like 
compounds on the SDN-POA. Potential developmental mechanisms underlying the 
expression of the sexual dimorphism of the SDN-POA. The role of neural stem cell 
activity in the development of the SDN-POA. Current progress in our studies exploring 
the mechanisms by which sex hormones and estrogen-like compounds affect the 
development of the SDN-POA. The sexually dimorphic nucleus is an easily modifiable 
structure that can serve as a model system for the study of how sex differences in brain 
structure and function arise and are maintained.  Processes underlying this phenomenon 
are highly clinically relevant for understanding the origins of sex biases in psychiatric 
syndromes and for identifying novel clinical targets. There is increasing evidence that 
perinatal exposure to estrogen or estrogen-like compounds may be associated with a host 
of health problems, including obesity and certain mental disorders such as depression.  
Bisphenol A (BPA), a compound found to be estrogen-like in some model systems, has 
been shown to alter the SDN-POA.  Thus, exploring the mechanisms by which BPA 
affects sexual dimorphic structures of the brain might lead to the development of new 
protective strategies and/or therapeutic approaches. 
 
 
 
 
 
 
 
